REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

SCIENTIFIC INFORMATION ON HEALTHCARE DISRUPTION

PIER MARIA FORNASARI
2021-04-13

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals.

Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. In a paper published on The Lancet it was investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. A large, multicentre, prospective cohort study was done, with participants

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-13

Letter from the Expert Haematology Panel and endorsed by Thrombosis UK, to the Medicines and Healthcare products Regulatory Agency (MHRA)

We wish to raise our concern with the MHRA regarding wording included in recent changes in MHRA guidance on the use of the AstraZeneca COVID-19 vaccine. The MHRA Guidance issued 7th April 2021 (https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots ) Indicates: The MHRA is not recommending age restrictions in COVID-19 Vaccine AstraZeneca use. As a precaution, administration of COVID-19 Vaccine AstraZeneca

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-12

World Federation of Hemophilia and European Hemophilia Consortium release joint statement on AstraZeneca COVID-19 vaccine

EMA, ISTH, WHO and many countries recommend benefit of COVID-19 vaccination outweighs the risks. Risks of adverse events no higher in people with bleeding disorders The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), following investigation of isolated cases of unusual blood clotting with low blood platelets that have occurred in a small number

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-10

University of Cambridge: Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine

All medical treatments have potential harms as well as potential benefits, and it’s important to be able to weigh these against each other. With vaccines, the benefits are particularly complex as they can involve benefits to others as well as to ourselves – and the harms can feel particularly acute because we take vaccines when

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-10

In two papers on NEJM researchers find VITT as responsible of AstraZeneca’s vaccine causing clots in 16 of 222 thrombosis EMA reported cases over 30 milion doses. Even US four J&J vaccine thrombosis cases under EMA evaluation scrutiny.

Doctors might have figured out why AstraZeneca Vaccine Induced Immune Thrombotic Thrombocytopenia (VITT) may cause life-threatening blood clots in a group of 16 patients with very rare cases of thrombosis and thrombocytopenia. The discovery, made in a pair of reports published online Friday in the New England Journal of Medicine, could be key to the global

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-10

New international consortium to promote stem cell-based therapy to treat Huntington’s disease

The Stem Cells for Huntington’s Disease ( SC4HD ) is a new international consortium created to drive advanced therapy drugs (ATMP), through stem cell transplantation, to treat Huntington’s disease. The entity, made up of twenty-eight renowned researchers from ten countries, has been officially featured in the Journal of Huntington’s Disease . The main objectives of the SC4HD consortium are to

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2021-04-09

Johnson & Johnson’s COVID-19 vaccine under EMA PRAC evaluation after 4 ‘serious cases’ of unusual blood clots

AstraZeneca’s COVID-19 vaccine has dominated headlines as reports of rare blood clots mounted, but, now, European drug safety regulators are investigating potential clotting risks from Johnson & Johnson’s vaccine. So far in the J&J vaccine’s U.S. rollout, EU officials have tracked three cases of unusual blood clots with low blood platelets following vaccination, the European

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-09

AstraZeneca COVID vaccine 70% effective vs B117 variant

Data from a UK phase 2/3 clinical trial suggest the AstraZeneca-Oxford COVID-vaccine is 70.4% effective against symptomatic COVID-19 caused by the B117 variant, which was identified in the United Kingdom in late 2020. The data, published in The Lancet yesterday, also showed it was 28.9% effective at preventing asymptomatic infections or cases with unknown symptoms. Overall efficacy was

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-09

An international working group (IWG) consensus report redefines outcomes in immune TTP

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy caused by autoantibody-mediated severe deficiency of ADAMTS13. Standardized definitions of response, exacerbation, remission, and relapse were initially proposed in 2003 and modified by the International Working Group for TTP in 2017. These definitions, which have been widely used in clinical practice and research, are

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2021-04-08

Antiparasitic drug could prevent Covid-19 lung damage

A common antiparasitic drug could block lung damage in people with coronavirus, new research published in Nature has found. Using robotic technology to screen over 3,000 approved drugs known to be safe in humans, researchers found Niclosamide – a drug used to treat tapeworm infections – was effective at stopping the viral replication and fusion

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-07

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

EMA confirms overall benefit-risk remains positive EMA’s safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-07

Guidance produced from the Expert Haematology Panel of British Society for Haematology focussed on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

An expert team of British Society for Haematology have recently been involved in diagnosing and managing a rare syndrome of thrombosis associated with low platelets which have been reported in a few cases. At the moment, any causal association with coronavirus vaccination has not been established. However, are identified patients with this syndrome in proximity

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-06

Ranking Virus Spillover Risk: New Web App Ranks Spillover Risk for Newly Detected Viruses

SARS-CoV-2 showed the world with devastating clarity the threat undetected viruses can pose to global public health. SpillOver, a new web application developed by scientists at the University of California, Davis, and contributed to by experts from all over the world, ranks the risk of wildlife-to-human spillover for newly discovered viruses. SpillOver is the first open-source risk

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-05

Recovered and vaccinated patients T cells recognize recent SARS-CoV-2 variants

NIH research suggests protective effects of vaccination remain intact When variants of SARS-CoV-2 (the virus that causes COVID-19) emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-04

First FDA approval of CAR T-cell therapy for multiple myeloma marks milestone for patients

Approval of ide-cel for adults who have relapsed after four or more prior lines of therapy follows clinical trials led by Dana-Farber Cancer Institute investigators The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers

No Comments InCAR-T

PIER MARIA FORNASARI
2021-04-04

Study underscores need for multidisciplinary care for COVID-19 long-haulers

Long COVID can affect multiple organ systems and the most common symptoms include fatigue, shortness of breath, brain fog, anxiety, depression, and post-traumatic stress disorder (PTSD) Based on the limited data available, at least one-third of patients hospitalized for COVID-19 studied to date have experienced such long-term effects Physicians across the country have analyzed the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-04-03

Globally Accessible Therapy Is Found to Protect Against Lethal Inflammation from COVID-19 in Animal Models

Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory genes has reduced morbidity and mortality in mice infected with SARS-CoV-2, the virus that causes COVID-19. In a study published today in the journal Cell, the team reported that the drug, Topotecan (TPT), inhibited the expression of inflammatory genes in the lungs

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-25

Potential COVID-19 treatment identified in UCLA-led lab study

Drug already in human trials as cancer therapy appears to disrupt coronavirus replication A collaboration among scientists from UCLA and other universities in California, Delaware and Germany, as well as a German pharmaceutical company, has singled out a compound that shows promise for treating SARS-CoV-2, the virus that causes COVID-19. In a series of experiments

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-25

A smartphone App can help to predict ‘Long COVID Syndrome’

As devastating as this pandemic has been, it’s truly inspiring to see the many innovative ways in which researchers around the world have enlisted the help of everyday citizens to beat COVID-19. An intriguing example is the COVID Symptom Study’s smartphone-based app, which already has been downloaded millions of times, mostly in the United States

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-25

SARS-CoV-2 infection of the oral cavity and saliva

NIH-funded findings point to a role for saliva in SARS-CoV-2 transmission. An international team of scientists has found evidence that SARS-CoV-2, the virus that causes COVID-19, infects cells in the mouth. While it’s well known that the upper airways and lungs are primary sites of SARS-CoV-2 infection, there are clues the virus can infect cells

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-25

Individual SARS-CoV-2 neutralising antibody immunity lasts from days to decades. Patients were categorized in 5 groups: negative, rapid waining, slow waining, persistent and delayed response.

Study shows that antibody longevity varies widely from 40 days to as long as several decades and not everyone who has recovered from COVID-19 is immune from reinfection Individuals with low levels of neutralising antibodies may still be protected if they have robust T-cell immunity Blood tests and a computer algorithm suggest annual vaccinations might

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-23

Gene therapy using “zinc fingers” may help treat Alzheimer’s disease, animal study shows

Key Takeaways A single injection of a gene therapy involving what are called zinc fingers dramatically reduced levels of tau, a protein implicated in Alzheimer’s disease, in mice with the condition. The treatment was long lasting, caused no side effects, and reduced Alzheimer’s-related damage in the brain. The technology worked just the way we had

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-03-23

Retroviral gene therapy with a view on previous experience and future perspectives

Gene therapy can be used to restore cell function in monogenic disorders or to endow cells with new capabilities, such as improved killing of cancer cells, expression of suicide genes for controlled elimination of cell populations, or protection against chemotherapy or viral infection. While gene therapies were originally most often used to treat monogenic diseases

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-03-23

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools forcombating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. Currently, more than 500 CAR-T and

No Comments InCAR-T

PIER MARIA FORNASARI
2021-03-23

U.S. NIAID discuss results released by AstraZeneca on Covid vaccine trial: AZ might have included outdated informations.

Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-22

Aspirin use may decrease ventilation, ICU admission and death in COVID-19 patients

Researchers from the George Washington University found that aspirin may have lung-protective effects and reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. George Washington University researchers found low dose aspirin may reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. Final results

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-22

Astrazeneca Covid vaccine US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis. No increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants.

79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation Comparable efficacy result across ethnicity and age,with 80% efficacy in participants aged 65 years and over Favourable reactogenicity and overall safety profile The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-21

AstraZeneca Covid vaccine and rare thrombosis: Greifswald team suggests an autoimmune trigger in 4 of 13 German reported cases. The incidence of thrombosis in Germany is 1:123.000 doses, while in the rest of Europe 1:1.350.000.

13 cases of a venous cerebral sinus or cerebral vein thrombosis following >1,6 million doses were reported in Germany. The thrombosis occurred 4-16 days after the vaccination with the AstraZeneca COVID-19 vaccine in twelve women and one man aged 20–63 years. The patients had one at the same time thrombosis and thrombocytopenia due to autoantibodies.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-19

New special warning introduced by EMA in the summary of COVID-19 Vaccine (ChAdOx1-S [recombinant]) product characteristics

EMA has just published the new product information leaflet for Astrazeneca Covid-19 vaccine after investigations of thrombosis rare cases reported. In the section 4.4 Special warnings and precautions for use has been added the following: Thrombocytopenia and coagulation disordersA combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, hasbeen observed very rarely following

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-19

A leap forward in research on CAR T cell therapy – Cellular engineering makes it possible to target the therapy also against solid tumours

A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumours in addition to leukaemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future. In cancer immunotherapy, cells in the patient’s

No Comments InCAR-T

PIER MARIA FORNASARI
2021-03-19

Optimal Thromboprophylaxis protocol in Patients With COVID-19

From the early days of the COVID-19 pandemic, a distinct coagulation disturbance of SARS-CoV-2 infection has been recognized. This thrombo-inflammatory phenotype, characterized by endotheliopathy, hypercoagulability, and coagulation activation, results in an increased risk of thromboembolic events. Initial observational cohort studies described high rates of venous thromboembolism (VTE) in critically ill patients with COVID-19, despite consistent use

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-19

Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2

In The Lancet, Zhenyu He and colleagues report their cross-sectional study of serological responses of morethan 9500 individuals from 3600 households in Wuhan, the early epicentre for the COVID-19 outbreak. The study was initiated shortly after lockdown in Wuhan ceased in April, 2020, with follow-up over two timepoints (June and October–December, 2020). In this cross-sectional,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-19

CDC US COVID-19 update on new SARS-CoV-2 Variants

CDC’s national genomic surveillance program identifies new and emerging SARS-CoV-2 variants to determine implications for COVID-19 diagnostics, treatments, or vaccines authorized for use in the United States. Monitoring the spread of emerging variants in the United States relies on widespread, rapid sequencing. To accelerate sequencing in the United States, CDC has contracted with commercial diagnostic laboratories, and,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-18

EMA Safety Committee confirms that COVID-19 Vaccine AstraZeneca benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets.

EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. The Committee confirmed that: the benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal)

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-18

A new study shows recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. A new potential role for human plasma transfusion.

Thrombosis affecting the pulmonary and systemic vasculature is common during severe COVID-19 and causes adverse outcomes. Although thrombosis likely results from inflammatory activation of vascular cells, the mediators of thrombosis remain unconfirmed. In a cross-sectional cohort of 36 severe COVID-19 patients, it was shown that markedly increased plasma von Willebrand factor (VWF) levels were accompanied

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-18

Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients

The main hypothesis of this retrospective study is that VWF biomarkers are associated with coagulation in COVID-19. It was performed a balanced retrospective study of COVID-19 hospitalized patients with similar demographics and comorbidities and a wide range of D-dimer levels to study how VWF biomarkers correlate with coagulation, intravascular hemolysis, and outcome. Indeed, we show

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-17

New Study from Cleveland Clinic Florida Researchers Points to Novel Drug Target for Treating COVID-19

Researchers from Cleveland Clinic’s Florida Research and Innovation Center (FRIC) have identified a potential new target for anti-COVID-19 therapies. Their findings were published in Nature Microbiology. Led by FRIC scientific director Michaela Gack, Ph.D., the team discovered that a coronavirus enzyme called PLpro (papain-like protease) blocks the body’s immune response to the infection. More research is necessary, but the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-17

A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 (South Africa) variant.

The SARS-CoV-2 spike gene has accumulated mutations within the receptor-binding domain (RBD) and the N-terminal domain (NTD). These domains are major targets of the antibody response elicited by the vaccines. The RBD mutations include the N501Y mutation, which is associated with increased affinity of SARS-CoV-2 to the angiotensin-converting enzyme 2 (ACE2) receptor. In contrast, the E484K

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-17

Astrazeneca Covid vaccine and blood clots: a storm in a teacup

A number of European nations, including Germany, France, Italy and Sweden, have suspended use of the Oxford/AstraZeneca covid‑19 vaccine over blood clot concerns. The World Health Organization and the European Medicines Agency (EMA) have both emphasised that there is currently no evidence linking the vaccine to blood clots and recommend that countries continue using it. Emer Cooke, director of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-15

How the pandemic has impacted teen mental health. Result of a Mott Poll Report

Restrictions put in place to contain COVID-19 may be particularly difficult for teens, who rely heavily on their peer and social connections for emotional support. In 2021, the C.S. Mott Children’s Hospital National Poll on Children’s Health asked a national sample of parents about the emotional impact pandemic restrictions have had on their teens age

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-15

Association of Acute Symptoms of COVID-19 and Symptoms of Depression in Adults

52,4% patients have symptoms of major depressive disorder after COVID-19, as published in a study of Massachusetts General Hospital More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder, according to a research letter published online March 12 in JAMA Network Open. Roy H. Perlis, M.D., from

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-14

Neutrophil activation tracks most closely with severe COVID-19 progression: a study on temporal and resolution dynamics of the host molecular responses confirms the main role of neutrophil proteolytic storm

The coronavirus disease-19 (COVID-19) pandemic has cost lives and economic hardships globally. Various studies have found a number of different factors, such as hyperinflammation and exhausted/suppressed T cell responses to the etiological SARS coronavirus-2 (SARS-CoV-2), being associated with severe COVID-19. However, sieving the causative from associative factors of respiratory dysfunction has remained rudimentary. In this

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-13

Vaccine-induced antibodies may be less effective against several new SARS-CoV-2 variants

Key Takeaways Neutralizing antibodies induced by the Pfizer and Moderna COVID-19 vaccines were significantly less effective against the variants first described in Brazil/Japan and South Africa. While the ability of these variants to resist neutralizing antibodies is concerning, it doesn’t mean the vaccines won’t be effective. Understanding which mutations are most likely to allow the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

Obesity linked to higher risk for poor COVID-19 outcomes

The risk for invasive mechanical ventilation, hospitalization and death in those with COVID-19 increased with BMI, according to research published in MMWR. “The findings in this report highlight a dose-response relationship between higher BMI and severe COVID-19–associated illness and underscore the need for progressively intensive illness management as obesity severity increases,” LyudmylaKompaniyets, PhD, a postdoctoral research fellow at the CDC,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

Protease inhibitors drugs Camostat and Nafamostat inhibit new SARS-CoV-2 activators identified in the upper respiratory tract, blocking virus cell entry.

There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing of already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development. The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

COVID-19 Vaccine and Blood Clots

Dr. Samuel Goldhaber, President of North American Thrombosis Forum (NATF) and Associate Chief and Clinical Director of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, answers the most pressing questions from patients about the COVID-19 vaccine and blood clots.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

UK Royal College of Physicians calls for urgent measures to protect and safeguard medical workforce involved in fight against Covid-19

In an article published in The Lancet, RCP president Professor Andrew Goddard and RCP Global vice president Dr Mumtaz Patel call for system-wide support to protect clinicians from harm. The COVID-19 pandemic has placed huge demands on global health systems which are testing doctors and health-care workers to the limits of their professional competence and taking

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

Early school reopening, in absence of a robust COVID-19 mitigation, risks accelerating the pandemic

On Feb 22, 2021, the UK Government announced that schools in England would fully reopen on March 8, 2021. While returning to school as soon as possible is imperative for the education, social development, and mental and physical welfare of children, not enough has been done to make schools safer for students and staff. Primary

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-12

A new study on BMJ shows an increase in deaths from 2.5 to 4.1 per 1000 detected cases in SARS-CoV-2 B.1.1.7 variant

A highly infectious variant of COVID-19 that has spread around the world since it was first discovered in Britain late last year is between 30% and 100% more deadly than previous dominant variants, researchers said on Wednesday. In a study that compared death rates among people in Britain infected with the new SARS-CoV-2 variant known

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-08

The challenges of CAR T-cell therapy for pediatric B-ALL. RESTORE launched Fragments of Life: A success in the frontier of medicine becomes a video game.

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, outlines the challenges associated with CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (ALL). Discovering the best treatment phasing with other immunotherapies, such as blinatumomab and inotuzumab, improving the toxicity profile, and CAR T-cell persistence are some of the remaining

No Comments InCAR-T

PIER MARIA FORNASARI
2021-03-06

Neurologic Involvement in Children and Adolescents Hospitalized in the US for COVID-19 or MISC

Most are transient, but some develop into life-threatening disorders Neurologic symptoms occurred frequently in children and adolescents hospitalized with COVID-19, a large case series of pediatric patients in the U.S. showed. Of 1,695 people 21 or younger hospitalized for acute COVID-19 or multisystem inflammatory syndrome in children (MIS-C), more than one in five (22%) had

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-05

New Google-Backed Database Tracks Details on SARS-CoV-2 and Variants Cases Worldwide

A group of US and European epidemiologists on Tuesday launched an open international database that presents granular information on 5 million anonymized COVID-19 cases from more than 100 countries. Each case record in the database, which is housed at Global.health, contains up to 40 variables, including information such as the patient’s demographics and location, the date

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-05

Can it work a single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster in a wide vaccination strategy ?

Vaccines to prevent COVID-19 infection are crucial for an effective global pandemic response. In The Lancet, Merryn Voysey and colleagues report the updated primary efficacy results for the Oxford–AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine from three single-blind, randomised controlled trials in the UK and Brazil and one double-blind study in South Africa. A subsequent report of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-04

SARS-CoV-2 B.1.1.7 (UK) variant is more transmissible with a 43%-90% higher reproduction number and could induce cases resurgences.

A variant of SARS-CoV-2 that emerged in southeast England in November 2020 is more transmissible than pre-existing variants, a new modeling study of Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, published on Science, finds. Further analyses suggest the variant B.1.1.7 will lead to large resurgences of COVID-19 cases.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-03-04

SARS-CoV-2 variant B.1.1.7 (so called UK) is susceptible to neutralizing antibodies elicited by wild type Spike vaccines

All current vaccines for COVID-19 utilize ancestral wild type SARS-CoV-2 Spike with the goal of generating protective neutralizing antibodies. The recent emergence and rapid spread of several SARS-CoV-2 variants carrying multiple Spike mutations raise concerns about possible immune escape. One variant, first identified in the United Kingdom (B.1.1.7, also called 501Y.V1 or 20I), contains eight

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-28

NIH Fauci and BARDA Disbrow: Janssen COVID-19 Vaccine proved 77% effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85% effective in preventing severe/critical COVID-19 occurring at least 28 days after vaccination.

“The Janssen COVID-19 vaccine is a very welcome addition to the arsenal of COVID-19 vaccines and other prevention strategies. When tested among 45,000 volunteers, the single-injection vaccine proved 77 percent effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85 percent effective in preventing severe/critical COVID-19 occurring at least 28 days

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-27

Carolina clinical trial tests effectiveness of mouthwash to kill oral SARS-CoV-2

Laboratory experiments have shown mouthwash can quickly kill coronaviruses, but there’s no evidence mouthwash can prevent the virus from infecting people. The Adams School of Dentistry is investigating how well mouthwash works to reduce the amount of SARS-CoV-2. Researchers at the University of North Carolina at Chapel Hill Adams School of Dentistry have launched a clinical trial to test

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-26

A paper published in NEJM shows that in Israel BNT162b2 mRNA Covid-19 Vaccine reduced cases by 94%

The Pfizer BioNTech coronavirus vaccine produces as good results in the “real world” as have been previously documented in randomised trials. A case control study, which has been peer reviewed and published in the New England Journal of Medicine, compared 596 618 people who were newly vaccinated in Israel and matched them to unvaccinated controls. Two doses

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

Causes of death and comorbidities in hospitalized patients with COVID-19: the majority of patients had died of COVID-19 with only contributory implications of preexisting health conditions to the mechanism of death.

Infection by the new corona virus strain SARS-CoV-2 and its related syndrome COVID-19 has been associated with more than two million deaths worldwide. Patients of higher age and with preexisting chronic health conditions are at an increased risk of fatal disease outcome. However, detailed information on causes of death and the contribution of pre-existing health

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

NCI study finds that people with SARS-CoV-2 antibodies may have a low risk of future infection

People who have had evidence of a prior infection with SARS-CoV-2, the virus that causes COVID-19, appear to be well protected against being reinfected with the virus, at least for a few months, according to a newly published study from the National Cancer Institute (NCI). This finding may explain why reinfection appears to be relatively rare,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

FDA analysis:Janssen COVID vaccine is safe and effective also against Brazil and South Africa variant

The Food and Drug Administration’s staff released a briefing document on Wednesday endorsing Johnson & Johnson’s one-shot coronavirus vaccine as safe and effective. An FDA advisory panel will meet Friday to review the briefing document and vote on whether to recommend an emergency use authorization (EUA). The FDA could then issue the (EUA) as soon as this

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

B.1.351 South Africa SARS-CoV-2 Variant is immune escaping but no increase in infectivity is shown in a paper on Cell

The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in Spike are now dominant in South Africa and are rapidly spreading to other countries. In this paper, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

Evidence of escape of SARS-CoV-2 variant B.1.351 (South Africa) from natural and vaccine induced sera. An analysis of AstraZeneca, Pfizer, Novavax and Janssen vaccine efficacy.

The race to produce vaccines against SARS-CoV-2 began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK–B.1.1.7, South Africa–B.1.351 and Brazil–P.1. These variants have multiple changes in the immunodominant spike protein which facilitates viral cell entry via the Angiotensin

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients

Despite dramatic improvements in survival, multiple myeloma (MM) remains largely incurable, and most patients develop disease that is refractory to available treatment options. A paper just published on Blood Advances by researchers of Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Westwood, Division of Gastroenterology, University of Toledo, Division of Hematology and

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-24

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly developed to help restore the massive health and economic disruption caused by the coronavirus disease 2019 (COVID-19) pandemic. In this just published paper on Cell researchers of Fondazione Toscana Life Sciences, National Institute for Infectious Diseases Lazzaro Spallanzani, Imperial College London and

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-24

European Society Blood and Marrow Transplantation Annual Report shows the rise of CAR-T Cells in Europe during year 2019 and changes in medical practices in the field of hematopoietic cell transplantation over 30 years.

Hematopoietic cell transplantation (HCT) is an established procedure for many acquired or inherited disorders of the hematopoietic system, benign or neoplastic, including those of the immune system, and as enzyme replacement in metabolic disorders. The activity survey of the EBMT, describing the status of HCT, has become an instrument with which to observe trends and

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-18

Immune system protects children from severe COVID-19

Children are protected from severe COVID-19 because their innate immune system is quick to attack the virus, a new study has found. The research led by the Murdoch Children’s Research Institute (MCRI) and published in Nature Communications, found that specialised cells in a child’s immune system rapidly target the new coronavirus (SARS-CoV-2). MCRI’s Dr Melanie Neeland said the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-13

Report of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021 shows 4,5 cases and 2,5 cases per million doses with Pfizer and Moderna respectively.

The cases of rash on mRNA vaccines are almost non-existent and no deaths have occurred. A research published in the medical journal JAMA, points out that the probability of developing anaphylaxis is only 0.000377%, as out of the approximately 17.5 million vaccinations, no deaths occurred, while only 66 people developed anaphylaxis to mRNA vaccines. A

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-12

Four potential COVID-19 therapeutics enter Phase 2/3 testing in NIH ACTIV-2 trial: between them Camostat mesilate, an orally administered serine protease inhibitor.

Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of promising COVID-19 treatments and vaccines. The new agents entering the randomized, placebo-controlled study are part of ACTIV-2, an adaptive trial designed to

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-12

Southern California COVID-19 Variant Rapidly Expands Global Reach

CAL.20C Variant, Now Found in Nearly Half of Southern California Cases, Is Detected in 19 US States, Washington, D.C., and Six Foreign Countries, Cedars-Sinai Reports A new strain of the coronavirus in Southern California, first reported last month by Cedars-Sinai, is rapidly spreading across the country and around the world as travelers apparently carry the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-12

NIH experts discuss SARS-CoV-2 viral variants: a Dr. Fauci’s paper on JAMA

Editorial emphasizes need for global response. The rise of several significant variants of SARS-CoV-2, the virus that causes COVID-19, has attracted the attention of health and science experts worldwide. In an editorial published today in JAMA: The Journal of the American Medical Association, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-12

Gene Therapy development is the result of a working team.

In drug development, scientific progression was never a solo effort. Rather, to advance new therapies, particularly cell and gene therapies, drug development is a team sport. Why is the team so important? Oftentimes when one tests novel cell and gene therapies in the clinic for the first time, one is treading completely new ground. The

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-02-11

IgM have a major role in the neutralizing activity of convalescent plasma against SARSCoV-2

Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-19, is essential to help control the infection. The neutralization activity of plasma from COVID-19 patients decreases rapidly during the first weeks after recovery. However, the specific role of each immunoglobulin isotype in the overall neutralizing capacity is still not well understood. In this

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-09

Artificial intelligence yields new ways to combat the coronavirus

Countering COVID-19 mutations and designing updated vaccines could occur at lightning speeds thanks to a new, USC-developed AI framework. USC researchers have developed a new method to counter emergent mutations of the coronavirus and hasten vaccine development to stop the pathogen responsible for killing thousands of people and ruining the economy. Using artificial intelligence (AI),

No Comments InARTIFICIAL INTELLIGENCE Covid-19

PIER MARIA FORNASARI
2021-02-08

A new study on Nature shows that BioNTech/Pfizer vaccine should neutralize SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants.

The Pfizer / BioNTech vaccine is effective against covid-19 variants originating in the UK and South Africa. This is the result of a study published this Monday in Nature Medicine , which showed better results in the first case, the British variant (called B.1.1.7), than in the second, the South African, or B.1.351. The differences, however, are small.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-08

University Health Network-led study shows Peginterferon lambda speeds up clearance of COVID-19 in outpatients

A clinical study led by Dr. Jordan Feld, a liver specialist at UHN’s Toronto Centre for Liver Disease, showed an experimental antiviral drug can significantly speed up recovery for COVID-19 outpatients – patients who do not need to be hospitalized. This could become an important intervention to treat infected patients and help curb community spread,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-08

Diffuse large B-cell lymphoma (DLBCL): FDA Grants Approval of 4th CAR-T Cell Therapy for Adults with Relapsed or Refractory DLBCL.

Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial Breyanzi demonstrated sustained responses in patients who achieved a CR with median duration of response not reached Grade ≥3 cytokine release syndrome and Grade ≥3 neurologic toxicities following Breyanzi treatment occurred in 4% and

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-08

Study highlights risk of new SARS-CoV-2 mutations emerging during chronic infection and after treatment with convalescent plasma

SARS-CoV-2 mutations similar to those in the B1.1.7 UK variant could arise in cases of chronic infection, where treatment over an extended period can provide the virus multiple opportunities to evolve, say scientists. Writing in Nature, a team led by Cambridge researchers report how they were able to observe SARS-CoV-2 mutating in the case of an

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-08

The mutation E484K, first identified in the South African SARS-CoV-2 variant, has now been identified in the UK fast-spreading variant

What do we know about the E484K mutation? The E484K mutation is not a new variant in itself, it’s a mutation which occurs in different variants and has already been found in the South African (B.1.351) and Brazilian (B.1.1.28) variants. The mutation is in the spike protein and appears to have an impact on the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-08

ORF9b from SARS-CoV-2, upon viral infection, antagonizes IFN-β and pro-inflammatory cytokines production mediating its interaction with NEMO and interrupting the K63-linked polyubiquitination of NEMO.

COVID-19 is a current global health threat caused by the novel coronavirus SARS-CoV-2. Emerging evidence indicates that SARS-CoV-2 elicits a dysregulated immune response and a delayed interferons (IFNs) expression in patients, which contribute largely to the viral pathogenesis and development of COVID-19. However, underlying mechanisms remain to be elucidated. In this paper, it’s reported the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

A two-dose regimen of the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant.

The Johannesburg Witwatersrand University Vaccines and Infectious Diseases Analytics (VIDA) Research Unit, which runs the Oxford Covid-19 vaccine trial in South Africa, has announced results. In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will perform an accelerated assessment of the Marketing Authorisation Application (MAA) for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel). Accelerated assessment is

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-07

A new study confirms the CDC prediction that B.1.1.7 UK variant will dominate US Covid-19 cases by March.

A more contagious variant of the coronavirus first found in Britain is spreading rapidly in the United States, doubling roughly every 10 days, according to a new study. Analyzing half a million coronavirus tests and hundreds of genomes, a team of researchers predicted that in a month this variant could become predominant in the United States,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

A not peer reviewed paper by London School of Hygiene finds a 35% increase of dying risk linked to the B.1.1.7 COVID-19 UK variant.

Since B.1.1.7 was first identified in September in southern England, it has become the dominant variant in the United Kingdom and has spread to more than 30 countries. To investigate whether the lineage causes an increased risk of dying, Nicholas Davies, an epidemiologist at the LSHTM, and colleagues analysed data from more than 850,000 people

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

Monoclonal Antibodies for Covid-19: an update

There are several approved treatments for coronavirus disease 2019 (COVID-19) in hospitalized patients but few for patients who are not sick enough to be hospitalized. Monoclonal antibodies are a new treatment for outpatients with COVID-19 who are at risk of progression to severe disease. What Is a Monoclonal Antibody? An antibody is a protein that is naturally

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

FDA narrows convalescent plasma Emergency Use Authorization

The US Food and Drug Administration (FDA) revised its emergency use authorization (EUA) for COVID-19 convalescent plasma to limit its use to high titer units and only in hospitalized patients who are in the early stages of the disease or who have impaired humoral immunity. Convalescent plasma emerged as a potential treatment for COVID-19 in the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-06

Computers can determine which could be COVID-19 patients clinical evolution

Using patient data, artificial intelligence can make a 90 percent accurate assessment of whether a person will die from COVID-19 or not, according to new research at the University of Copenhagen. Body mass index (BMI), gender and high blood pressure are among the most heavily weighted factors. The research can be used to predict the

No Comments InCovid-19 DIGITAL HEALTH

PIER MARIA FORNASARI
2021-02-06

Investigating the modulation of the COVID-19 immune response

In a recent paper, the research team around Prof. Antonio del Sol from the University’s Luxembourg Centre for Systems Biomedicine (LCSB) describes a new method of how molecules can be identified that amplify and maintain the inflammatory response upon an infection. They use their novel method to identify these molecules in COVID-19 patients and suggest new

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-06

SARS-CoV-2 vaccines: how to communicate the current situation

How do vaccines work? Germs are all around us, both in our environment and in our bodies. When a person is susceptible and they encounter a harmful organism, it can lead to disease and death. The body has many ways of defending itself against pathogens (disease-causing organisms). Skin, mucus, and cilia (microscopic hairs that move debris away

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-05

SARS-CoV-2 directly infects human erythroid progenitors: implications for emerging erythropoiesis in severe COVID19 patients.

The COVID-19 pandemic continues to constitute a huge threat to public health worldwide and despite the efforts and advances to untangle the mechanisms of SARS-CoV-2 infection and transmission among humans, we are still blind to the overall COVID-19 pathology and its consequences. The results presented in this paper might help understand the emergent erythropoiesis and

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-03

Lack of ICU beds tied to thousands of excess COVID-19 deaths in US.

A new study by Yale researchers found a significant association between the availability of hospital resources — particularly ICU beds — and patient mortality during the early weeks of the COVID-19 pandemic. This was especially true at hospitals in the northeastern U.S. which were hardest hit by the first surge of patient cases, according to

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-03

Understanding COVID-19: how mRNA vaccines work. A Yale University video.

What is RNA? How do mRNA vaccines work, and how effective are they? What does this mean for the COVID-19 pandemic? In a short video, Yale experts Saad Omer, Onyema Ogbuagu, and Akiko Iwasaki explain the science.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-03

Moffitt Researchers Identify Why CAR T Therapy May Fail in Some Lymphoma Patients

Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-03

Heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac “Sputnik V” Found 91,6% Effective Against COVID-19: a study published on The Lancet shows

A Russian vaccine against COVID-19 — Gam-COVID-Vac (dubbed “Sputnik V”) — shows 92% efficacy in interim results from a phase 3 trial reported in The Lancet. The two-dose vaccine uses replication-deficient adenoviruses to deliver a SARS-CoV-2 glycoprotein as the antigenic stimulus. Doses are administered at 21-day intervals, and the vaccine may be stored in normal freezers.

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-03

The timing of the booster dose is determinant for improval of immunogenicity and efficacy of ChAdOx1 (Oxford Astra Zeneca ) nCoV-19 (AZD1222) vaccine

The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, MHRA, with a regimen of two standard doses given with an interval of between 4 and 12 weeks. The planned rollout in the UK will involve vaccinating people in high risk categories with their first dose immediately, and delivering

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-02

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

In one of the most puzzling and worrisome developments in the pandemic, scientists are racing to explain what’s happening in Manaus, Brazil, a city of 2.2 million at the edge of the country’s rainforest that is experiencing a second explosive outbreak, even though the first one was so bad it was thought to have produced

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-01

Covid-19: B.1.1.7 new UK variant patients present more commonly sore throat, fatigue, and myalgia for Office for National Statistics

People infected with the new variant of covid-19 discovered in the South East of England (known as B.1.1.7 or VUI 202012/01) are more likely to have a cough, sore throat, fatigue, or myalgia than those infected with other variants, the Office for National Statistics has reported. The data, published 27 January, also show that people

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-01

Arizona University Researchers Develop Smartphone-Based COVID-19 test that uses a smartphone microscope and could deliver results in about 10 minutes.

Researchers at the University of Arizona are developing a COVID-19 testing method that uses a smartphone microscope to analyze saliva samples and deliver results in about 10 minutes. The UArizona research team, led by biomedical engineering professor Jeong-Yeol Yoon, aims to combine the speed of existing nasal swab antigen tests with the high accuracy of nasal swab PCR,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-01

33% can be the proportion of SARS-CoV-2 Infections That Are Asymptomatic for a Systematic Review

In the 14 studies with longitudinal data that reported information on the evolution of symptomatic status, nearly three quarters of persons who tested positive but had no symptoms at the time of testing remainedasymptomatic. Current data suggest that infected persons without symptoms—including both presymptomatic and asymptomatic persons—account for more than 40% of all SARS-CoV-2 transmission.

No Comments InCovid-19 Uncategorized

PIER MARIA FORNASARI
2021-02-01

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial shows reduction risk of heart failure hospitalizations.

1. Treatment with IV ferric carboxymaltose reduced the risk of heart failure hospitalizations in patients with iron deficiency and acute heart failure with a left ventricular ejection fraction less than 50%. 2. IV ferric carboxymaltose was generally safe but had no significant effect on the risk of cardiovascular death compared to placebo. Evidence Rating Level: 1

No Comments InRESEARCH

PIER MARIA FORNASARI
2021-01-31

For CDC, in-Person Schools May Reopen with Precautions as Data Shows Scant Virus Spread

U.S. schools operating in-person have experienced low transmission of the Chinese coronavirus, particularly when mitigation strategies such as masking and social distancing are in place, U.S. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky stressed on Friday, citing new findings by the health agency. Under President Joe Biden, the CDC has expressed support

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-31

SARS-CoV-2 VS vaccines and the threat of mutations

The key question in 2021 is whether the new strains of coronavirus will be able to eradicate the vaccine-induced immunity. This paper on JAMA by John P Moore and Paul A Offit of Cornell and Pennsylvania Universities has been recently published on JAMA. The protection that vaccines provide against COVID-19 infection is mediated primarily by

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-29

Who does and who doesn’t benefit from steroids for Covid-19. Results from a meta-analyses of RCTs.

Efficacy and safety of corticosteroids in patients with SARS-CoV-2 infection still are debated. Because large randomized clinical trials (RCTs) and a well-conducted meta-analysis on the use of corticosteroids, focused on patients with coronavirus disease (COVID-19) in intensive care units, recently were published, a meta-analysis of RCTs on corticosteroids therapy in patients with different disease severity

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-29

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

An international team of researchers has characterized the effect and molecular mechanisms of an amino acid change in the SARS-CoV-2 Spike protein N439K. Viruses with this mutation are both common and rapidly spreading around the globe. The peer reviewed version of the study appears January 25 in the journal Cell. Investigators found that viruses carrying this

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-25

The Future of Organ Transplants: Bioprinting, Stem Cells and More. A paper of Polylactide.com

In the United States alone, over 100,000 people are on the organ transplant list. Around 17 of these people will die per day without having received the transplant. It’s clear that organs from human donors will never be adequate for everyone looking for a transplant. Thus, scientists have been researching alternatives, such as using organs made from repurposed stem

No Comments InBIOPRINTING

PIER MARIA FORNASARI
2021-01-25

The effects of armed conflict on the health of women and children. More than 10 million deaths in children <5 years can be attributed to conflict between 1995 and 2015 globally.

Women and children bear substantial morbidity and mortality as a result of armed conflicts. This paper published in The Lancet focuses on the direct (due to violence) and indirect health effects of armed conflict on women and children (including adolescents) worldwide. It was estimate that nearly 36 million children and 16 million women were displaced

No Comments InETHICS INFORMATION

PIER MARIA FORNASARI
2021-01-25

A Clalit study shows decreased infection in SARS-CoV-2 due to the Pfizer vaccine

The Clalit Research Institute is currently examining the effect of the vaccine against the coronavirus developed by Pfizer. Preliminary data show that 14 days after the injection of the first vaccine, there is a real decrease in the rate of infection in the corona . The study compared the infection data of about 200,000 people aged 60 and over who

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-25

CDC reports 2,5 Anaphylaxis Cases per million Moderna Covid-19 vaccine doses in USA.

As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days). On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Moderna COVID-19 vaccine administered as 2 doses, 1 month apart to

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-23

Creating a Safe CAR T-Cell Therapy to Fight Solid Tumors in Children

Scientists at Children’s Hospital Los Angeles develop newer CAR T therapy that promises to be more effective and less toxic for children with neuroblastoma. Chimeric Antigen Receptor T-cell therapy—CAR T—has revolutionized leukemia treatment. Unfortunately, the therapy has not been effective for treating solid tumors including childhood cancers such as neuroblastoma. Preclinical studies using certain CAR

No Comments InCAR-T

PIER MARIA FORNASARI
2021-01-22

11,1 cases per million doses Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Following implementation of vaccination, reports of anaphylaxis after the first dose of the Pfizer-BioNTech COVID-19 vaccine emerged.Anaphylaxis is a life-threatening allergic reaction that occurs rarelyafter vaccination, with onset typically within minutes to hours.Notifications and reports of suspected severe allergic reactions and anaphylaxis following vaccination were captured in the Vaccine Adverse Event Reporting System (VAERS), the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-22

Emergence of a novel SARS-CoV-2 strain in Southern California, USA

Researchers in Cedars-Sinai Medical Center, Los Angeles found that the variant, originated in California, was present in more than half of samples tested last week by researchers in Los Angeles. In late December, scientists in California began searching coronavirus samples for a fast-spreading new variant that had just been identified in Britain. They found it, though in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-22

Review of the epidemiology, susceptibility to infection, pathophysiology, immunology, complications, potential therapeutic options and response to vaccinations in people with diabetes, obesity and metabolic disorders showing mortality excess due to SARS-CoV-2 infection.

The increased prevalence of obesity, diabetes and cardiovascular risk factors in people hospitalized with severe COVID-19 illness has engendered considerable interest in the metabolic aspects of SARS-CoV-2-induced pathophysiology. In this paper published in Cell Metabolism are updated concepts informing how metabolic disorders and their comorbidities modify the susceptibility to, natural history and potential treatment of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-22

A study shows early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. In this paper published on Cell Reports are interrogated the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death. SARS-CoV-2 viral RNA in the respiratory tract in parallel

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-21

Autoantibodies role suspected in severe Covid-19 patients

Evidence is growing that self-attacking ‘autoantibodies’ could be the key to understanding some of the worst cases of SARS-CoV-2 infection. More than a year after COVID-19 emerged, many mysteries persist about the disease: why do some people get so much sicker than others? Why does lung damage sometimes continue to worsen well after the body

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-21

New study shows that BioNTech-Pfizer SARS-CoV-2 vaccine protects against highly infectious UK variant

A new study found that antibodies in patients vaccinated against COVID-19 were able to neutralize a version of the new variant. Researchers tested 10 mutations of the B117 variant, which was first identified in the UK. The COVID-19 vaccine developed by BioNTech and Pfizer is likely to protect against the highly infectious variant of the virus, originally found

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-21

Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19, due to its inhibition of neutrophil serine proteases “unfriendly fire”.

No definitive treatment for COVID-19 exists although promising results have been reported with remdesivir and glucocorticoids. Short of a truly effective preventive or curative vaccine against SARS-CoV-2, it is becoming increasingly clear that multiple pathophysiologic processes seen with COVID-19 as well as SARS-CoV-2 itself should be targeted. Because alpha-1-antitrypsin (AAT) embraces a panoply of biologic

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-20

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 501Y.V2, a novel lineage of the coronavirus causing COVID-19, contains multiple mutations within two immunodominant domains of the spike protein. In a paper recently published on https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1.full.pdf it’s shown that this lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies. Furthermore 501Y.V2 shows substantial or complete escape from neutralizing antibodies in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-20

B.1.1.7 SARS-CoV-2 (UK) and other variants description

At the heart of each coronavirus is its genome, a twisted strand of nearly 30,000 “letters” of RNA. These genetic instructions force infected human cells to assemble up to 29 kinds of proteins that help the coronavirus multiply and spread. As viruses replicate, small copying errors known as mutations naturally arise in their genomes. A lineage of coronaviruses will

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-19

Update on new SARS-CoV-2 emerging variants (UK, South Africa, Brazil and California)

What do we know about the new variant emerging from Brazil? This variant, known as P.1 or VOC202101/02 in the UK, was first detected in travellers from Brazil who arrived in Japan in January 2021. It involves 17 unique amino acid changes, three deletions, four synonymous mutations, and one 4nt insertion. It has several mutations

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-19

Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug

Research conducted by the University of Bari in collaboration with the Campus Bio-Medico University of Rome The studies carried out by the research team of the University of Bari in collaboration with the Campus Bio-Medico University of Rome, formed by Luigi Leonardo Palese, Anna Maria Sardanelli, and Camilla Isgrò of the Department of Basic Medical

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-18

Could Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise Hopes

A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Both therapies work by switching on a gene that promotes production of fetal hemoglobin, said Dr. Lewis Hsu, chief medical officer of the Sickle Cell Disease Association

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-01-17

Saliva tests may be just as good as nasopharingeal swabs for COVID-19

COVID-19 tests that use patients’ saliva to screen for the virus are just as effective as those that use swabs collected from the nose and throat, an analysis published by JAMA Internal Medicine found. Saliva-based tests correctly identified those infected with the new coronavirus 83% of the time, while nose-throat swab tests were 85% accurate, the review of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-16

For CDC the more contagious SARS-CoV-2 B.1.1.7 variant may soon be the U.S.’s dominant strain

On December 14, 2020, the United Kingdom reported a SARS-CoV-2 variant of concern (VOC), lineage B.1.1.7, also referred to as VOC 202012/01 or 20I/501Y.V1.* The B.1.1.7 variant is estimated to have emerged in September 2020 and has quickly become the dominant circulating SARS-CoV-2 variant in England (1). B.1.1.7 has been detected in over 30 countries,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-16

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19, due to no convincing evidence of the effect on clinical outcomes.

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19. Since May 2020, the RECOVERY trial has included a randomised comparison of convalescent plasma vs. usual care alone. Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-15

The Future of CAR T cells in multiple myeloma

Despite the significant improvement in survival outcomes of multiple myeloma (MM) over the past decade, it remains an incurable disease. Patients with triple-class refractory MM have limited treatment options and a dismal prognosis. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen has transformed the treatment armamentarium of relapsed/refractory MM (RRMM), with unprecedented overall

No Comments InCAR-T

PIER MARIA FORNASARI
2021-01-12

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19: observational study published in Gut BMJ.

Imbalances in type and volume of bacteria may also be implicated in ‘long COVID’ The variety and volume of bacteria in the gut, known as the microbiome, may influence the severity of COVID-19 as well as the magnitude of the immune system response to the infection, suggests research published online in the journal Gut. Imbalances in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-12

EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca. Marketing authorisation could be issued by 29 January

EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. The assessment of the vaccine, known as COVID-19 Vaccine AstraZeneca, will proceed under an accelerated timeline. An opinion on the marketing authorisation could be issued by 29 January during the meeting of EMA’s scientific committee for human medicines (CHMP), provided

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

A CDC study published on JAMA shows that People without symptoms spread SARS-CoV-2 in more than half of cases.

A model developed by CDC researchers estimates that 59% of coronavirus cases in the United States are spread by asymptomatic carriers. Transmissions from individuals who have not yet begun to exhibit signs of infection account for 35% of that total, while transmissions from people who never develop symptoms make up the other 24%. A model

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

Regulatory perspectives of Exosomes as therapeutics and drug delivery vehicles

Exosomes are nano-sized extracellular vesicles secreted by all cells. Extensive research over recent years has now shown these vesicles to be important players in intercellular signalling and to have a role in tissue regeneration, immunomodulation and other biological functions. A lipid bilayer protects the exosome cargo of nucleic acids and proteins from degradation and permits

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2021-01-11

Placental Protection : Three studies examine coronavirus and antibodies during pregnancy

Pregnant women infected with SARS-CoV-2 appear to be at higher risk of developing severe cases of COVID-19 than infected women who are not pregnant. Yet newborns are mostly doing well. Reports indicate that only about 5 percent of babies born to COVID-19-infected mothers are themselves infected, and most newborns who test positive have mild or

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

Candida Auris Outbreak in a COVID-19 Specialty Care Unit in Florida

Dozens of people being treated for COVID-19 at a Florida hospital last summer became additionally infected with a mysterious, often deadly fungus called Candida auris, a US government study said Friday. The multidrug-resistant yeast was first identified in Japan in 2009 and has been a top priority for the Centers for Disease Control and Prevention

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

Study finds higher burden of acute brain dysfunction for COVID-19 ICU patients

COVID-19 patients admitted to intensive care in the early months of the pandemic were subject to a significantly higher burden of delirium and coma than is typically found in patients with acute respiratory failure. Choice of sedative medications and curbs on family visitation played a role in increasing acute brain dysfunction for these patients. That’s

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

For U.K. health officials, Interleukin-6 inhibitors (Tocilizumab or Sarilumab) should be prescribed to adult patients admitted to ICU with Covid-19 pneumonia.

Clinicians should consider prescribing intravenous tocilizumab following the criteria defined below for patients in intensive care. Intravenous sarilumab could be considered as an alternative (if available).Any provider organisation treating patients with this intervention will be required to assure itself that the internal governance arrangements have been completed before either medicine is prescribed. These arrangements may

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-11

An In Vitro Study Shows Pfizer-Biontech COVID-19 Vaccine Elicits Neutralizing Antibodies against SARS-COV-2 with N501Y Mutation

Pfizer Inc. and BioNTech SE announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. The results were published

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-10

What we know about genetic variants of SARS-CoV-2

When we speak of variants we refer to differences in the sequence of the genome due to mutations. Strain is a variant in which changes in its biology are demonstrated (antigenicity, transmissibility, virulence,…). For now, let’s talk about variants. The evaluation of the new variants should answer these questions: Has the new variant appeared by

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-08

FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff

Impact on molecular tests remains low The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-08

Orchard Therapeutics with research alliance partners Fondazione Telethon and Ospedale San Raffaele Milan Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)

First gene therapy to receive full EU marketing authorization for eligible MLD patients. One-time treatment with Libmeldy has been shown to preserve motor and cognitive function. Orchard Therapeutics, a global gene therapy leader, and its research alliance partners Fondazione Telethon and Ospedale San Raffaele, today announced that the European Commission (EC) granted full (standard) market authorization

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2021-01-08

DNA-editing method shows promise to treat mouse model of progeria

Using a recently developed DNA base-editing technique, researchers correct accelerating aging disorder. Researchers have successfully used a DNA-editing technique to extend the lifespan of mice with the genetic variation associated with progeria, a rare genetic disease that causes extreme premature aging in children and can significantly shorten their life expectancy. The study was published in the journal Nature, and was

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2021-01-07

Stem cell treatment corrects skull shape and restores brain function in mouse model of childhood disorder

Scientists regenerate parts of the skull affected by craniosynostosis, a common birth defect. Using stem cells to regenerate parts of the skull, scientists corrected skull shape and reversed learning and memory deficits in young mice with craniosynostosis, a condition estimated to affect 1 in every 2,500 infants born in the United States, according to the

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2021-01-07

ApoE isoform-dependent SARS-CoV-2 neurotropism and cellular response

ApoE4, a strong genetic risk factor for Alzheimer’s disease, has been associated with increased risk for severe COVID-19. However, it is unclear whether ApoE4 alters COVID-19 susceptibility or severity and the role of direct viral infection in brain cells remains obscure. In this paper, published in Cell Stem Cells, the Authors tested the neurotropism of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-07

Early IgG titer greater than 1:1000 against SARS-CoV-2 spike protein Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness. In this paper, published on NEJM, the Authors conducted a randomized, double-blind, placebo-controlled trial of convalescent plasma with high

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-06

The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19

Corticosteroid therapy is now recommended as a treatment in patients with severe COVID-19. But one key question is how to objectively identify severely ill patients who may benefit from such therapy. In a paper just published on Cell Metabolism, 12,862 COVID-19 cases from 21 hospitals in Hubei Province were equally assigned to a training and

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-05

Mutations arising in SARS-CoV-2 spike on sustained human-to-human transmission and human-to-animal passage

The proximal origins of SARS-CoV and MERS-CoV from civets and camels, respectively, are well documented. Few genetic changes in these viruses are required for the interspecies transfers to humans. While precise details and timing of the evolutionary pathways remain to be elucidated, it is also apparent that SARS-CoV-2 emerged from the Sarbecovirus subgenus of the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-05

SARS-CoV-2 Variants

SARS-CoV-2, the virus that causes COVID-19, has had a major impact on human health globally; infecting a large number of people; causing severe disease and associated long-term health sequelae; resulting in death and excess mortality, especially among older and vulnerable populations; interrupting routine healthcare services; disruptions to travel, trade, education and many other societal functions;

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-01

New SARS-CoV-2 variants described by researchers of University College of London and Cambridge University

Does it spread more easily? Make people sicker? Mean that treatments and vaccines won’t work? Questions are multiplying as fast as new variants of the coronavirus, especially the one moving through England and now popping up in the U.S. and other countries. Scientists say there is reason for concern and more to learn but that

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-01

Microvascular Injury in the Brains of Patients with Covid-19. The damage was not caused by a direct viral attack on the brain.

In an in-depth study of how COVID-19 affects a patient’s brain, National Institutes of Health researchers consistently spotted hallmarks of damage caused by thinning and leaky brain blood vessels in tissue samples from patients who died shortly after contracting the disease. In addition, they saw no signs of SARS-CoV-2 in the tissue samples, suggesting the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-30

Oxford University/AstraZeneca Covid-19 vaccine approved by UK MHRA

The new vaccine has been approved today after meeting the required safety, quality and effectiveness standards. The COVID-19 vaccine developed by Oxford University/AstraZeneca has today been given regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA) after meeting required safety, quality and effectiveness standards. Following a rigorous, detailed scientific review by the MHRA’s

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-29

Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients With COVID-19 and Myocardial Infarction

Severe coronavirus disease 2019 (COVID-19) is characterized by the intense formation of neutrophil extracellular traps (NETs), leading to the occlusion of microvessels, as shown in pulmonary samples. The occurrence of ST-elevated myocardial infarction (STEMI) is a serious cardiac manifestation of COVID-19; the intrinsic mechanism of coronary thrombosis appears to still be unknown. Objective of the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-29

One Year Later, How Does COVID-19 Affect Children?

Children get sick less often than adults due to Covid-19, but children are at risk. This is the key insight from a paper in the Journal of American Medical Association (JAMA), a peer-reviewed medical journal, as the year draws to an end. The paper summarizes the current understanding of how children are affected by Covid-19. So far

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-28

SARS-CoV-2 vaccine update

Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 64 vaccines in clinical trials on humans, and 19 have reached the final stages of testing. At least 85 preclinical vaccines are under active

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-27

D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction

The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. In this paper are explored spike conformational changes and the effects of

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-27

Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19

The SARS-CoV-2 pandemic poses an unprecedented public health crisis. Evidence suggests that SARS-CoV-2 infection causes dysregulation of the immune system. However, the unique signature of early immune responses remains elusive. In this paper the transcriptome of rhesus macaques and mice infected with SARS-CoV-2 was characterized. Alarmin S100A8 was robustly induced in SARS-CoV-2 infected animal models

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-20

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Recently a distinct phylogenetic cluster (named lineage B.1.1.7) was detected within the COG-UK surveillance dataset. This cluster has been growing rapidly over the past 4 weeks and since been observed in other UK locations, indicating further spread. Several aspects of this cluster are noteworthy for epidemiological and biological reasons and we report preliminary findings below.

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-18

Which appropriate SARS-CoV-2 test to select.

There’s a growing variety and availability of tests related to SARS-CoV-2. All types of tests can help healthcare providers make more accurate diagnosis, support better management of individual patients and provide better guidance to manage population risk. Active infection is detected with RT-PCR tests detect the presence of SARS-CoV-2 based on its genetic make up (RNA). These tests

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-18

By October 2020 COVID-19 had become the third leading cause of death in US for persons aged 45 through 84 years and the second for those aged 85 years or older.

Adults 45 years or older were more likely to die from COVID-19 during those months than from chronic lower respiratory disease, transport accidents (eg, motor vehicle fatalities), drug overdoses, suicide, or homicide. In contrast, for individuals younger than age 45 years, other causes of death, such as drug overdoses, suicide, transport accidents, cancer, and homicide

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-16

Teaching youngsters about the magnificent world of Advanced Therapies. RESTORE Consortium experiences a new formation/information tool for disseminating CAR-T Cells Therapy in Haematologic diseases.

“Thanks to this technology and to the specific fighting capabilities of these cells, extraordinary results have been obtained: The therapy is a new hope for patients who no longer responded to other treatments. The therapy seems to have a long-lasting effect after a single application Unlike many other therapies, which benefit only a small portion

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2020-12-15

Research Could Offer Novel Way to Restore Lung Function to COVID-19 Patients

Targeting endothelial cells –cells that comprise the blood vessel wall which regulate oxygen exchange between airways and the bloodstream– may be a novel approach restoring normal lung function to Covid-19 patients with serious lung disease. This hypothesis stems from a study by researchers in the Department of Microbiology and Immunology in the Renaissance School of

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-15

Covid-19 fighting: New Online Resources

There are lots of useful online resources to learn about COVID-19 and some of the clinical studies taking place across the country. What’s been missing is a one-stop online information portal that pulls together the most current information for people of all groups, races, ethnicities, and backgrounds who want to get involved in fighting the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-14

Data Monitoring Committee of Pluristem Phase III Critical Limb Ischemia says primary endpoint has not been reached

The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the study to meet its primary endpoint PLX-PAD was well tolerated, and no safety concerns were raised Company to terminate the CLI study to focus on different therapeutic areas in its pipeline and expects three clinical readouts within the coming calendar year

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2020-12-12

New Online COVID-19 Mortality Risk Calculator Could Help Determine Who Should Get Vaccines First

CALCULATOR GENERATES MORTALITY RISK ESTIMATES FOR INDIVIDUALS AND COMMUNITIES BASED ON SOCIODEMOGRAPHIC INFO AND MEDICAL HISTORY A new online calculator for estimating individual and community-level risk of dying from COVID-19 has been developed by researchers at the Johns Hopkins Bloomberg School of Public Health. The researchers who developed the calculator expect it to be useful to

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-12

Genes could be key to new Covid-19 treatments

Potential treatments for Covid-19 have been identified after the discovery of five genes associated with the most severe form of the disease. Genetic evidence is second only to clinical trials as a way to tell which treatments will be effective in a disease. Existing drugs that target the actions of the genes reveal which drugs

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-11

Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic

During the coronavirus disease 2019 (COVID-19) pandemic, the general public has been advised to wear masks or improvised face coverings to limit transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there has been considerable confusion and disagreement regarding the degree to which masks protect thewearer from airborne particles. To evaluate the fitted filtration

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-11

Repurposed Antiviral Drugs for Covid-19 —Interim WHO Solidarity Trial Results confirmed none of tested drugs reduced mortality

World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir and interferon beta-1a) in patients hospitalized with Covid-19. Inpatients with Covid-19 were randomly assigned equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-11

FDA Vaccines and Related Biological Products Advisory Committee Recommends COVID-19 Vaccine For Emergency Use

In a 17-4 vote, with one abstention, a panel of advisers to the Food and Drug Administration recommended Thursday that the COVID-19 vaccine being developed by Pfizer and BioNTech be authorized for emergency use during the coronavirus pandemic. The vote in favor of the vaccine was taken to answer the agency’s question: Do the benefits

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-10

Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARSCoV-2-Infected Cells

Previous studies reported on the safety and applicability of mesenchymal stem/stromal cells (MSCs) to ameliorate pulmonary inflammation in acute respiratory distress syndrome (ARDS). Thus, multiple clinical trials assessing the potential of MSCs for COVID-19 treatment are underway. Yet, as SARS-inducing coronaviruses infect stem/progenitor cells, it is unclear whether MSCs could be infected by SARS-CoV-2 upon

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2020-12-10

COVID-19, cold, allergies and the flu: What are the differences?

COVID-19, the common cold, seasonal allergies and the flu have many similar signs and symptoms. Find out about some of the important differences between these illnesses. If you have signs or symptoms of coronavirus disease 2019 (COVID-19), it’s important that you contact your doctor or clinic right away for medical advice. But COVID-19, the common cold,

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-10

COVID-19’s sex bias based on a large-scale global statistical analysis: men more at risk of requiring critical care

Sex should be considered an important biological factor when designing therapies and vaccination strategies for COVID-19. Global-scale collaboration between scientists has taken on new forms in the midst of the COVID-19 pandemic, with connection underpinning the work. A paper investigating the role of sex in patients infected with COVID-19 is the result of a partnership between researchers

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-09

Researchers at Gladstone Institutes Identify Critical Molecules that Coronaviruses Hijack to Infect Human Cells

When a coronavirus—including SARS-CoV-2, which causes COVID-19—infects someone, it hijacks the person’s cells, co-opting their molecular machinery for its own survival and spread. Researchers at Gladstone Institutes and the Chan Zuckerberg Biohub, in collaboration with scientists at UC San Francisco (UCSF) and Synthego Corporation, have identified critical molecular processes in human cells that coronaviruses use

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-08

3D VR video on CAR-T therapy to learn more about how this innovative technology is being used to tackle MultipleMyeloma.

The Janssen Pharmaceutical Companies of Johnson & Johnson unveils longer-term results from the combined Phase 1b/2 CARTITUDE-1 study evaluating ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed and/or refractory multiple myeloma. Cilta-cel is an experimental BCMA-directed (B cell maturation antigen) chimeric antigen receptor T cell (CAR-T) therapy. Data presented at the ongoing Annual Meeting

No Comments InCAR-T

PIER MARIA FORNASARI
2020-12-08

Oxford–AstraZeneca COVID-19 vaccine efficacy: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK published on The Lancet

2020 has been a difficult year for all, but has seen 58 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) be developed and in clinical trials, with some vaccines reportedly having more than 90% efficacy against COVID-19 in clinical trials. This remarkable achievement is much-needed good news as COVID-19 cases are currently at their

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-07

New CRISPR-Based Test for COVID-19 Uses a Smartphone Camera

A team of scientists from Gladstone, UC Berkeley, and UC San Francisco outlined the technology for a rapid, one-step mobile test that could help combat the pandemic and fully reopen communities. Imagine swabbing your nostrils, putting the swab in a device, and getting a read-out on your phone in 15 to 30 minutes that tells

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-05

Presented CAR T ZUMA-5 phase 2 study data for non-Hodgkin lymphoma

Earlier this year, Caron Jacobson, MD, presented the interim analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. Results from that interim analysis showed that the vast majority of patients with follicular lymphoma or marginal zone lymphoma – two slow-growing forms of non-Hodgkin lymphoma – responded to and

No Comments InCAR-T

PIER MARIA FORNASARI
2020-12-04

Moderna mRNA-1273 Vaccination produced serum neutralizing antibodies detected in all the participants at day 119

Vaccine “has the potential to provide durable humoral immunity” against virus, NIAID authors argue Antibody responses to Moderna’s COVID-19 vaccine candidate, mRNA-1273, remained strong for almost 4 months following vaccination, data from a phase I trial indicated. Serum neutralizing antibodies were detected in 34 healthy adult volunteers at day 119 following the first dose, and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-02

Toward superhuman SARS-CoV-2 immunity?

Vaccines against covid could give “superhuman immunity”, stronger than if the disease is passedThe researchers Dennis Burton and Eric Topol have published in ‘Nature’ a correspondence in which they address the perspectives of the immunity of vaccines, comparing the available data on covid vaccines with those on vaccines against other diseases. They are optimistic that

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-01

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

The coronavirus can reach the human brain after it is inhaled through a person’s nose and becomes trapped in the nasal mucus, a study found. It is the first known evidence that the coronavirus can infect neurons of the brain through the mucosal pathway. In the course of the pandemic, it has become clear that

No Comments InCovid-19

PIER MARIA FORNASARI
2020-12-01

Penn Medicine Researchers Unlock the Door to Tumor Microenvironment for CAR T Cells

PAK4 inhibitor improved T cell infiltration and shrank solid tumors in mice The labyrinth of jumbled blood vessels in the tumor microenvironment remains one of the toughest blockades for cellular therapies to penetrate and treat solid tumors. Now, in a new study published online today in Nature Cancer, Penn Medicine researchers found that combining chimeric antigen receptor (CAR)

No Comments InCAR-T

PIER MARIA FORNASARI
2020-11-27

PEDSnet Report Details How COVID-19 Pandemic Has Affected Children

Analysis of 135,000+ medical records shows the novel coronavirus hits hardest among teens, children with diabetes or cancer, lower-income families, and Black, Latin and Asian groups. In the most comprehensive analysis to date of U.S. children tested and treated for COVID-19, an organization representing seven of the nation’s largest pediatric medical centers reports that some

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-27

Big Data Powers Design of ‘Smart’ Cell Therapies for Cancer

Combining Machine Learning with Cell Engineering, Scientists Can Design ‘Living Medicines’ that Precisely Target Tumors Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research. In two new papers, scientists at UC San Francisco and Princeton University present complementary strategies to crack this problem with “smart”

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2020-11-26

CAR T-Cell Research is surging accompanied by a diversification of development and manufacturing pathways.

Hundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since

No Comments InCAR-T

PIER MARIA FORNASARI
2020-11-26

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia fails to shows significant clinical benefit as compared with placebo.

Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials. In this paper researchers of the Clinical Pharmacology Section, Hospital Italiano de Buenos Aires, Juan D. Perón, Buenos Aires, Argentina as

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-25

Drug guides stem cells to desired location, improving their ability to heal

Discovery represents a major milestone for regenerative medicine that could help more people benefit from stem cell therapy. Scientists at Sanford Burnham Prebys Medical Discovery Institute have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy—a scientific first and a major advance for the field of regenerative medicine. The

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2020-11-25

Most Americans are still vulnerable to SARS-CoV-2 virus. Seroprevalence over 4 collection periods ranged from less than 1% to 23%

As of September, the vast majority of Americans did not have coronavirus antibodies, according to a new study published in JAMA Internal Medicine. These data matter as the coronavirus spreads rapidly throughout most of the country, most people remain vulnerable to it. Across the U.S., the portion of states’ populations with detectable antibodies ranged from less

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-24

Insulin treatment is associated with increased mortality in patients with COVID-19

COVID-19 caused by SARS-COV2 infection can lead to multi-organ injuries and significant mortality in severe and critical patients, especially among those individuals with type 2 diabetes (T2D) as a comorbidity. While attenuated mortality was observed with aggressive glucose control, it was unclear whether therapeutic regiments including insulin treatment was beneficial for patients with COVID-19 and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-24

Antibodies capable of neutralising SARS-CoV-2 persist for at least 3 months in most Covid-19 patients, even those who had mild disease.

The SARS-CoV-2 virus is causing a global pandemic and cases continue to rise. Most infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that could contribute to immunity. In this paper, published on Cell, it’s performed a longitudinal assessment of individuals recovered from mild

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-22

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis published on EClinicalMedicine.

Early reports indicated that in COVID-19 may be associated with coagulation dysfunction. Studies have reported varying rates of thromboembolism. In this paper, the Authors searched PubMed, Cochrane and Embase for systematic reviews and meta-analyses evaluating thromboembolism rates in COVID-19 published until June 12, 2020. The search terms were “COVID-19”, “SARS-CoV-2” or “novel coronavirus” and “venous

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-20

Oxford coronavirus vaccine produces strong immune response in older adults as published in The Lancet

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published in The Lancet, suggest that one of the groups most vulnerable to serious illness, and death from COVID-19, could build

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-20

The Most Logical Approach to Improve CAR T Cell Therapy: a preview on Cell Systems

Combinational antigen recognition is the most logical way to improve the safety of cancer therapy. CAR T cells therapy, combined with synthetic biology, protein engineering, and bioinformatics, can perform advanced computations to enhance tumor targeting specificity. Immunotherapy, including biologic and cellular approaches, is a critical area of focus for cancer therapeutics. Of the methodologies used

No Comments InCAR-T

PIER MARIA FORNASARI
2020-11-20

Baricitinib treatment linked to reduced mortality in COVID-19 patients

The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden. The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials. “We are pleased to

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-20

Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19

As of 20 November 2020, the number of COVID-19 cases was reported to be more than 57 million, leading to more than 1.361,000 deaths worldwide . Elevated levels of CRP, cytokine and chemokines, together with low lymphocyte and eosinophil counts, characterize patients with severe disease. However, a reliable biomarker of poor outcome in COVID-19 is

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-19

In the lab, St. Jude scientists redefine cytokine storm and identify possible COVID-19 treatment

Immunologists have determined the process driving life-threatening inflammation, lung damage and organ failure in patients with COVID-19, sepsis and other inflammatory disorders suggesting possible treatment using existing drugs. The COVID-19 pandemic continues to cause significant illness and death while treatment options remain limited.St. Jude Children’s Research Hospital scientists have discovered a potential strategy to prevent life-threatening

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-18

Pfizer and BioNTech conclude Phase 3 study of Covid-19 Vaccine candidate, meeting all primary efficacy endpoints

Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-17

Data released by the American Academy of Pediatrics and the Children’s Hospital Association find that more than 1 million kids have now been diagnosed with Covid-19.

State-level reports are the best publicly available data on child COVID-19 cases in the United States. The American Academy of Pediatrics and the Children’s Hospital Association are collaborating to collect and share all publicly available data from states on child COVID-19 cases (definition of “child” case is based on varying age ranges reported across states;

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-17

For an Oxford University research, videogaming is positively correlated with well-being. RESTORE consortium videogame “Fragments of Life” helps to enter into CAR-T Cells breakthrough therapy in Acute Lymphoblastic Leukemia.

Conventional wisdom has it that too many cooks spoil the broth. But such judiciousness is not usually considered the basis for scientific pronouncements or international rulings on the need to limit the number of people in kitchens. But, when it comes to video games, conventional wisdom, not science, forms the basis for our thinking and

No Comments InADVANCED THERAPY MEDICINAL PRODUCT CAR-T

PIER MARIA FORNASARI
2020-11-16

CAR-T cell therapy as a “game changer” therapy in paediatric acute lymphoblastic leukaemia: past, present and future. A review of the British Society for Haematology.

Over the last decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising treatment modality for relapsed/refractory B-cell malignancies in both children and adults. As an adoptive immune therapy, CAR-T cells have the potential to overcome disease that is resistant to chemoand radiotherapy as well as represent a viable option for those who

No Comments InCAR-T

PIER MARIA FORNASARI
2020-11-16

Clinical Trial of NIH-Moderna COVID-19 Vaccine: Positive Interim Results

An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 15, 2020. This interim review of the data suggests that the vaccine is safe and effective at preventing symptomatic

2 comments InCovid-19

PIER MARIA FORNASARI
2020-11-15

Dissecting the immune characteristics of severe COVID-19 responses: Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19

Key points: Researchers have analysed immune cell types and numbers from the blood of healthy volunteers, COVID-19 patients experiencing mild-to-moderate effects and patients classified as severe to understand whether particular characteristics of their immune system response can identify treatment targets or indicate disease severity. After comparing the T cell immune response, the researchers noted the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-15

Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. SARS-CoV-2 infection of pancreatic endocrine cells, via ACE2, is an unlikely central pathogenic feature.

Diabetes is associated with increased mortality from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Given literature suggesting a potential association between SARS-CoV-2 infection and diabetes induction, it was examined pancreatic expression of angiotensin-converting enzyme-2 (ACE2), the key entry factor for SARS-CoV-2 infection. Specifically, in this paper published on Cell Metabolism, were analyzed five public scRNA-seq pancreas

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-15

A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways: an investigation on the phylogenetic characteristics of SARS-CoV-2 infections in Chicago.

The rapid spread of SARS-CoV-2, the causative agent of Coronavirus disease 2019 (COVID-19), has been accompanied by the emergence of distinct viral clades, though their clinical significance remains unclear. In this paper it’s investigated the phylogenetic characteristics of SARS-CoV-2 infections in Chicago, Illinois, and assessed their relationship to clinical parameters. Whole-genome sequencing of SARS-CoV-2 isolates

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-14

A Series of Disappointing Results of Immune-Based Therapies for COVID-19

It’s been a tough couple of weeks for immune-based therapies for COVID-19. We know that immune modulation in this disease, especially in its most severe manifestations, can improve outcomes. Favorable results from the RECOVERY study of dexamethasone have made it the standard of care for most hospitalized patients who require oxygen. And we also know that our own immune

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-14

Treatments for People with Early COVID-19 Infection is an Urgent Research Focus, according to a JAMA Viewpoint article by NIAID Director Anthony S. Fauci, M.D., and colleagues.

Effective, Early Interventions would Benefit Individual Patients and Healthcare System COVID-19 treatments for people with early infection are needed urgently, according to a JAMA Viewpoint article by NIAID Director Anthony S. Fauci, M.D., and colleagues. Treating people early in the course of infection with SARS-CoV-2, the virus that causes COVID-19, would speed their recovery, reduce

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-14

Real-time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles with four distinct FRET efficiency states, enhanced by proteolysis. Convalescent plasma antibodies exert a double action.

SARS-CoV-2 spike (S) mediates viral entry into cells and is critical for vaccine development against COVID-19. Structural studies have revealed distinct conformations of S, but real-time information that connects these structures, is lacking. In this paper it’s applied single-molecule Fluorescence (Förster) Resonance Energy Transfer (smFRET) imaging to observe conformational dynamics of S on virus particles.

6 comments InCovid-19

PIER MARIA FORNASARI
2020-11-13

Inhaled nebulised Interferon beta-1a may help Covid-19 patients, in a randomised, double-blind, placebo-controlled, phase two trial.

An inhaled form of interferon — a drug commonly used to treat multiple sclerosis by injection — may help protect hospitalized Covid-19 patients from getting worse, according to a British drugmaker. Results were first released in July, but were published Thursday as a peer-reviewed study in The Lancet Respiratory Medicine. The body naturally releases interferon when

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-12

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. A Randomized Clinical Trial

An obsessive compulsive disorder (OCD) drug may help improve the conditions of coronavirus patients, a new study suggests. Fluvoxamine, sold under the brand name Luvox, is a medication that scientists believe has anti-inflammatory properties, which can help control the immune system’s overreaction to the virus. No patient who was given the drug suffered from shortness of breath

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-11

Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US FDA

To understand the usual approval process followed by the FDA, researchers of the Yale University School of Medicine have systematically evaluated all novel vaccines approved by the FDA over the last decade, characterizing the premarket development and regulatory review times, the clinical evidenceon which approval was based, and the size and follow-up duration of the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-10

FDA issues EUA for Bamlanivimab Monoclonal Antibody for Treatment of mild-to-moderate COVID-19

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is authorized for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-10

Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Running NIH clinical trial in association with remdesivir.

SARS-CoV-2 induced hypercytokinemia and inflammation are critically associated with COVID19 disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor, is currently being investigated in COVID-19 clinical trials. In this paper published on Cell, are investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-09

Hydroxychloroquine does not benefit adults hospitalized with COVID-19

A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. Though found not to cause harm, early findings in June when the trial was stopped indicated that the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-09

Final report of the NIAID Adaptive COVID-19 Treatment Trial (ACTT-1) confirms remdesivir benefits for COVID-19

Remdesivir is an antiviral medication that targets a range of viruses. It was originally developed over a decade ago to treat hepatitis C and a cold-like virus called respiratory syncytial virus (RSV). Remdesivir wasn’t an effective treatment for either disease. But it showed promise against other viruses. Researchers tested remdesivir in clinical trials during the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-09

Gene therapy technique to regenerate the optic nerve offers hope for future glaucoma treatment

Scientists at University of Cambridge have used gene therapy to regenerate damaged nerve fibres in the eye, in a discovery that could aid the development of new treatments for glaucoma, one of the leading causes of blindness worldwide. Axons – nerve fibres – in the adult central nervous system (CNS) do not normally regenerate after

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2020-11-06

COVID-19 lung damage caused by persistence of ‘abnormal cells’

Investigations of deceased COVID-19 patients have shed light on possible lung damage caused by the virus. The study, published today in The Lancet’s eBioMedicine, by King’s in collaboration with University of Trieste and the International Centre for Genetic Engineering and Biology in Italy, shows the unique characteristics to the SARS-CoV-2 virus and may explain why

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-03

New Cause of COVID-19 Blood Clots Identified. Half of the patients with severe COVID-19 exhibits a combination of high levels of antiphospholipids antibodies and NET’s: dipyridamole potential therapy.

A new study reveals the virus triggers production of antibodies circulating through the blood, causing clots in people hospitalized with the disease. Blood clots continue to wreak havoc for patients with severe COVID-19 infection, and a new study explains what may spark them in up to half of patients. The culprit: an autoimmune antibody that’s

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-02

Coagulopathy as a Prodrome of Cytokine Storm in COVID-19-Infected Patients

Integrated analysis revealed a positive correlation of coagulopathy withcytokine storm in COVID-19-infected patients; the D-dimer rises early, which indicates that coagulopathy acts as a prodrome of cytokine storm. Coagulopathy can be used to monitor early cytokine storm in COVID-19-infected patients. Coagulopathy appeared around a few days in advance of a cytokine storm. It was also

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-02

New Landmark Study at UM School of Medicine Finds Aspirin Use Reduces Risk of Death in Hospitalized COVID-19 Patients

Hospitalized Patients Who Were Taking Daily Aspirin Had Lower Risk of ICU Admission, Ventilation, and Dying from the Virus Hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin, according to a new

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-02

NIH researchers discover that β-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway

Targeting cells’ ‘trash compactor’ could lead to new antiviral strategy to fight COVID-19. Researchers at the National Institutes of Health have discovered a biological pathway that the novel coronavirus appears to use to hijack and exit cells as it spreads through the body. A better understanding of this important pathway may provide vital insight in

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-01

What to make of “re-positive” SARS-CoV-2 molecular test results

In a Commentary on EBioMedicine researchers of Icahn School of Medicine at Mount Sinai, New York try to solve the enigma between dead viral particles testing or real clinical reinfection. Nine months after the first reports describing a novel corona virus (Severe Acute Respiratory Syndrome coronavirus 2, SARS-CoV-2) causing severe disease in humans (coronavirus Disease

No Comments InCovid-19

PIER MARIA FORNASARI
2020-11-01

New York University researchers using leukemia-on-a-chip dissect the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche. A new opportunity for CAR-T cells therapy improving.

B cell acute lymphoblastic leukemia (B-ALL) blasts hijack the bone marrow (BM) microenvironment to form chemoprotective leukemic BM “niches,” facilitating chemoresistance and, ultimately, disease relapse. However, the ability to dissect these evolving, heterogeneous interactions among distinct B-ALL subtypes and their varying BM niches is limited with current in vivo methods. In this paper , New

No Comments InCAR-T

PIER MARIA FORNASARI
2020-10-31

Aprotinin Inhibits SARS-CoV-2 Replication and is identified as a potential drug candidate for Covid-19 treatment. Can human plasma have the same effect?

Researchers from the University of Kent, the Goethe-University in Frankfurt am Main (Germany), and the Hannover Medical School (Germany) have identified a drug with the potential to provide a treatment for COVID-19. The international team led by Professor Martin Michaelis, Dr. Mark Wass (both School of Biosciences, University of Kent), and Professor Jindrich Cinatl (Institute

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-31

A new report of London Imperial College shows COVID-19 fatality ratio estimated from seroprevalence is about 1%

The COVID infection fatality ratio is around 1% in high-income countries, but substantially lower in low-income countries with younger populations. These are the findings of a new report from the Imperial College London COVID-19 Response Team. The report reveals that: In high income countries, the estimated overall infection fatality ratio (IFR) is 1.15% (95% prediction interval

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-31

A direct drive parallel plane piezoelectric needle positioning robot for MRI guided intraspinal injection

Lower back pain caused by degenerative disc disorder affects approximately 40% of the population over 40 and though many of us may never experience adverse effects from the disorder, it is the cause of chronic back pain for numerous Americans. Recent imaging diagnostics and cellular based direct-injection therapeutics for degenerative disc and spinal cord injuries

No Comments InROBOTIC SURGERY

PIER MARIA FORNASARI
2020-10-30

Early results from DETECT study suggest fitness trackers and smartwatches can predict COVID-19 infection

Sensor data from wearable devices can complement virus testing and conventional screening to signal new infections. Examining data from the first six weeks of their landmark DETECT study, a team of scientists from the Scripps Research Translational Institute sees encouraging signs that wearable fitness devices can improve public health efforts to control COVID-19. The DETECT study, launched

No Comments InCovid-19 DIGITAL HEALTH

PIER MARIA FORNASARI
2020-10-29

COVID-19 Immune Response Study of the ISB-Swedish COVID-19 Immune Response Study Could Lead to More Effective Treatments

The ISB-Swedish COVID-19 Immune Response Study has revealed new findings that suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The symptoms of COVID-19 vary widely, from very mild to severe conditions requiring ICU care. Researchers comprehensively studied a large number of patients during the week

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-28

New inflammatory disorder called vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic syndrome (VEXAS) discovered by NIH researchers

Researchers from the National Institutes of Health (NIH) have discovered a new inflammatory disorder called vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic syndrome (VEXAS), which is caused by mutations in the UBA1 gene. VEXAS causes symptoms that included blood clots in veins, recurrent fevers, pulmonary abnormalities and vacuoles (unusual cavity-like structures) in myeloid cells. The scientists reported

No Comments InRARE DISEASES

PIER MARIA FORNASARI
2020-10-27

Use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure: a review published on npj regenerative medicine.

In patients with critical manifestations of COVID-19, life-threatening complications such as ARDS and multiple organ dysfunction are mediated by extensive inflammation, neutrophils recruitment, cytokine storm syndrome and dysregulated immune innate responses. MSCs because of their immunomodulatory, regenerative, and antimicrobial properties could render several therapeutic effects in the setting of COVID-19. While data from countless clinical

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-26

FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy in non-Hodgkin’s Lymphoma.

Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin’s lymphoma Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-001,

No Comments InCAR-T

PIER MARIA FORNASARI
2020-10-25

COVID-19 and Lombardy: TESTing the impact of the first wave of the pandemic. Seroprevalence in the Bergamo area is 38.5%.

The emergence of a novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused a major disease outbreak that posed a threat to public health worldwide. Among the western countries, Italy was the first to experience a vast Coronavirus Disease 2019 (COVID-19) outbreak and the province of Bergamo experienced the deadliest COVID-19 outbreak in theworld. Due

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-24

Researchers of NEI use gene therapy and a novel light-sensing protein to restore vision in mice

NIH-funded therapy will now be tested in humans A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2020-10-24

Masks could cut COVID-19 deaths in the US by 130,000: IHME COVID-19 Forecasting Team study shows

Even if state-level governments in the United States reimpose limited social distancing measures to halt the spread of COVID-19, the death toll could more than double by the end of February 2021 to 511,000, according to projections released Friday. Near-universal mask wearing over the coming months could reduce that grim tally by nearly 130,000, researchers

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-24

Neutrophils express non-canonical functions, including vascular repair and hematopoietic homeostasis.

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have discovered that neutrophils, the most abundant cells of the innate immune system, have many more functions in the body than previously thought. This finding suggests possible new treatments for many diseases, including cancer. In a study published in the journal Cell, the research team demonstrates that

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2020-10-23

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Researchers have identified a second receptor that might be important in SARS-CoV-2 infectivity, according to a new report published in Science on October 20. This cofactor helps facilitate virus-host cell interactions in cells with low levels of angiotensin-converting enzyme 2 (ACE2), the primary receptor on host cells, and might explain the increased pathogenicity of SARS-CoV-2. Why is

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-23

In an open label phase II multicentre randomised controlled trial (PLACID Trial) convalescent plasma isn’t associated with a reduction in disease progression or all cause mortality in moderate Covid-19.

Convalescent plasma may not prevent progression to severe disease or reduce mortality risk in hospitalized patients with moderate COVID-19, based on a phase 2 trial involving more than 400 patients in India. The PLACID trial offers real-world data with “high generalizability,” according to lead author Anup Agarwal, MD, of the Indian Council of Medical Research,

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-14

SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF-barrier in human brain organoids.

Coronavirus disease-19 (COVID-19), caused by the SARS-CoV-2 virus, leads to respiratory symptoms that can be fatal. However, neurological symptoms have also been observed in some patients. The cause of these complications is currently unknown. In this paper, were use human pluripotent stem cell-derived brain organoids to examine SARS-CoV-2 neurotropism. Was found expression of viral receptor

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-13

NIH launched the ACTIV-5/BET study, a randomized, double-blind, placebo-controlled trial testing risankizumab or lenzilumab +remdesivir in Covid-19 treatment.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial, which will enroll adult volunteers hospitalized

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-13

Therapeutic Management of Patients with COVID-19. Updated Treatment Guidelines released by NIH.

A number of investigational agents and drugs that are approved for other indications are currently being studied in clinical trials for the treatment of COVID-19 and associated complications. Data from randomized controlled trials, prospective and retrospective observational cohorts, and case series studies are rapidly emerging. The COVID-19 Treatment Guidelines Panel (the Panel) continues to review

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-13

For NIH updated treatment guidelines, insufficient data from well-controlled, adequately powered, randomized clinical trials to evaluate the efficacy and safety of convalescent plasma for the treatment of COVID-19.

Last Updated: October 9, 2020 Plasma from donors who have recovered from COVID-19 may contain antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may help suppress the virus and modify the inflammatory response.1 Recommendation There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-13

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. Lopinavir-Ritonavir no benefit in patients admitted.

No reductions seen in 28-day mortality or duration of hospital stay in COVID-19 with lopinavir-ritonavir. Lopinavir-ritonavir is not associated with reductions in 28-day mortality or duration of hospital stay among patients admitted to the hospital with COVID-19, according to a study published online Oct. 5 in The Lancet. Peter W. Horby, M.D., Ph.D., and colleagues on

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-12

COVID-19 and Excess All-Cause Mortality in the US and 18 Comparison Countries. Research letter on JAMA.

Was compared the US to Organisation for Economic Co-operation and Development countries with populations exceeding 5million and greater than $25 000 per capita gross domestic product. For each country, was calculated the COVID-19 per capita mortality rate and grouped countries by mortality: (1) low (COVID-19 deaths, <5/100 000), (2) moderate (5-25/ 100 000), and (3)

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-12

Clinical Development of Gene Therapies: The First Three Decades and Counting.

In the past three decades the field of gene therapy has made remarkable progress surging from mere laboratory experiments to FDA-approved products which bring significant reduction in disease burden to patients who previously had no therapeutic options for their serious conditions. In this paper it’s reviewed the evolution of the gene therapy clinical research landscape

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2020-10-11

Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study published on EClinicalMedicine

Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection is associated with hypercoagulability caused by direct invasion of endothelial cells and\or proinflammatory cytokine release. Thromboprophylaxis with enoxaparin is recommended by current guidelines, but evidence is still weak. The aim of this study was to assess the impact of thromboprophylaxis with enoxaparin on hospital mortality in patients

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-11

RESTORE community has released new position paper on advanced therapies.

The RESTORE position paper represents the cumulative efforts of the RESTORE community, and the steering committee since the start of the RESTORE initiative in 2019. It outlines, in depth, the RESTORE view on why Europe should invest in Advanced Therapies, the roadblocks in Advanced Therapy development and implementation into patient care, and makes recommendations about

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2020-10-11

The role for the metagenome and the influence of microbiota on immune processes in the pathogenesis of COVID-19 infection.

A new paper published on EBioMedicine analyzes metagenome contribution to Covid-19 response variability. A key question concerning COVID-19 is why most infected persons do not develop severe disease, while others become critically ill. This dichotomy is related to age, gender, immunosuppression and comorbidities, but many persons who are young succumb to the virus. A significant

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-10

Neutrophil proteolytic enzymes storm triggers vascular disease and thrombosis in SARS-CoV-2 infected Rhesus Macaques

The COVID-19 pandemic has led to extensive morbidity and mortality throughout the world. Clinical features that drive SARS-CoV-2 pathogenesis in humans include inflammation and thrombosis, but the mechanistic details underlying these processes remain to be determined. In this study, was demonstrated endothelial disruption and vascular thrombosis in histopathologic sections of lungs from both humans and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-08

SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host interferons

SARS-CoV-2 is a recently identified coronavirus that causes the respiratory disease known as COVID-19. Despite the urgent need, it’s not fully understood the molecular basis of SARS-CoV-2 pathogenesis. In this paper, are comprehensively defined the interactions between SARS-CoV-2 proteins and human RNAs. NSP16 binds to the mRNA recognition domains of the U1 and U2 splicing

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-08

A large-scale Multi-omic Analysis shows neutrophil degranulation, vessel damage, platelet activation and degranulation, blood coagulation and complement activation are responsible for COVID-19 Severity

RNA-Seq and high-resolution mass spectrometry on 128 blood samples from COVID-19 positive and negative patients with diverse disease severities and outcomes were performed and published on Cell Systems Quantified transcripts, proteins, metabolites, and lipids were associated with clinical outcomes in a curated relational database, uniquely enabling systems analysis and cross-ome correlations to molecules and patient

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-07

Sarilumab use in severe SARS-CoV-2 pneumonia. IL-6 blockade inhibits neutrophil recruitment and innate immune response harm.

Interleukin-6 signal blockade showed preliminary beneficial effects in treating inflammatory response against SARS-CoV-2 leading to severe respiratory distress. In this paper, published on EClinicalMedicine are described the outcomes of off-label intravenous use of Sarilumab in severe SARS-CoV-2-related pneumonia. 53 patients with SARS-CoV-2 severe pneumonia received intravenous Sarilumab; pulmonary function improvement or Intensive Care Unit (ICU)

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-06

Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19

The contribution of CD4 + T cells to protective or pathogenic immune responses to SARS-CoV-2 infection remains unknown. In this paper it’s presented single-cell transcriptomic analysis of >100,000 viral antigen-reactive CD4 + T cells from 40 COVID-19 patients. In hospitalized patients compared to non-hospitalized patients, were found increased proportions of cytotoxic follicular helper (T FH

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-01

COVID-19 and Heart Failure With Preserved Ejection Fraction

The more common manifestation in the COVID-19 era may be HFpEF related primarily to the unmasking of subclinical HFpEF and secondarily to the development of new HFpEF following infection with SARS-CoV-2. Patients with preexisting cardiovascular disease (CVD) who develop coronavirus disease 2019 (COVID-19) have worse outcomes than patients without CVD.Infection with severe acute respiratory syndrome

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-01

Fewer than 10% of the US adult population formed antibodies against SARS-CoV-2, and fewer than 10% of those with antibodies were diagnosed.

Fewer than 10 percent of the U.S. adult population formed antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first wave of the pandemic, according to a study published online Sept. 25 in The Lancet. Shuchi Anand, M.D., from the Stanford University School of Medicine in Palo Alto, California, and colleagues conducted a cross-sectional

No Comments InCovid-19

PIER MARIA FORNASARI
2020-10-01

New randomized clinical trial suggests Hydroxychloroquine failure even as a COVID19 preventative in healthcare workers

In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19. Despite promising early reports and strong in vitro performance, Hydroxychloroquine (HCQ) has become the major therapeutic disappointment of the COVID pandemic. Research

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-28

An English study shows people infected with Covid-19 and flu have higher risk of death.

Research in England shows a dangerous relationship between the viruses that cause both diseases; for those in the ICU with co-infection, the risk of death is 6.33 times higher. People infected at the same time by the new coronavirus and the flu virus are twice as likely to die than those infected by Sars-Cov-2 alone . This is the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-28

This week’s Offline column by The Lancet Editor-in-Chief defines Covid-19 Syndemic not Pandemic.

Two categories of disease are interacting within specific populations—infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and an array of non-communicable diseases (NCDs). These conditions are clustering within social groups according to patterns of inequality deeply embedded in our societies. The aggregation of these diseases on a background of social and economic disparity exacerbates

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-27

A multicenter cardiovascular pathology study shows various features of COVID-19-associated myocardial injury

Early in the pandemic, other clinicians noted that even some patients who didn’t have preexisting heart conditions experienced cardiovascular damage while fighting COVID-19 infections, pointing to a possible causative link. Researchers had found, for example, that 8–12 percent of hospitalized COVID-19 patients had elevated levels of muscle contraction–regulating proteins called troponins—a sign of heart damage—and that these

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-27

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Currently, no Food and Drug Administration (FDA)-approved therapeutics exist for coronavirus disease 2019 (COVID-19). In this context, the pandemic has put considerable pressure on health care providers to prescribe treatments despite limited information about their safety and efficacy. This pressure has exacerbated the tension between the importance of practicing evidence-based medicine and the urgency of

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-26

Scientists discover 13,5% cases of severe Covid-19 present genetic and immunologic underpinnings inducing type I Interferon lacking

New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19. The researchers found that more than 10% of people who develop severe COVID-19 have

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-26

Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis

Children were less likely than adults to acquire a COVID-19 infection from an index case, a meta-analysis found. Across 32 contact tracing or population testing studies comparing SARS-CoV-2 prevalence in children and adults, children younger than 14 were less likely to be infected from an index case overall (odds ratio 0.56, 95% CI 0.37-0.85), and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-25

Gastrointestinal Complications in Critically Ill Patients With and Without COVID-19

COVID-19 appears to have significant extrapulmonary complications affecting multiple organ systems. Critically ill patients with COVID-19 oftendevelop gastrointestinal complications during their hospital stay, including bowel ischemia, transaminitis, gastrointestinal bleeding, pancreatitis, Ogilvie syndrome, and severe ileus. Whether the high incidence of gastrointestinal complications is a manifestation of critical illness in general or is specific to COVID-19

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-23

Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy

Chimeric antigen receptor (CAR) technology and its application to regulatory T cells (Tregs) has garnered interest among researchers in the field of cell and gene therapy. Merging the benefits of CAR technology with Tregs offers a novel and promising therapeutic option for durable reshaping of undesired immune responses following solid organ or hematopoietic stem cell

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2020-09-23

People with asymptomatic SARS-CoV-2 infection have an upper respiratory viral load as those with mild symptoms

They are relatively common so may act as important driver of viral spread, warn researchers People with ‘silent’ COVID-19 infection have as much coronavirus in their noses and throats as those with symptoms, reveals research published online in the journal Thorax. Given how many of these people there are—a fifth of those infected, the study findings show–they may

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-21

Modulating endothelial adhesion and migration impacts stem cell therapies efficacy

Despite the first clinical studies reporting on a correlation betweenthe migration potential of transplanted stem cells and their therapeutic efficacy, it is unclear if effective stem cell therapies requirereliable and sufficient delivery of the cells to the desired anatomiclocations, as well as survival of the cellular graft. Moreover, the many complex processes involved in stem

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2020-09-17

FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C)

First-of-its kind study to be supported by the Cura Foundation, The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now The Cura Foundation in collaboration with The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now, is supporting a clinical trial of human cord tissue mesenchymal stromal cells (hCT-MSC) to treat children with

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-16

Frequency of Children vs Adults Carrying Severe Acute Respiratory Syndrome Coronavirus 2 Asymptomatically

The frequency of children carrying asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been suggested to be higher than among adults. It is also suggested that asymptomatic children enhance viral spread. A research letter by published in the journal JAMA Pediatrics in September 2020 explores the truth of this common belief. Earlier Research Earlier studies

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-16

Efficacy of convalescent plasma against COVID19 requires early therapy with high titer plasma. RCTs need to be designed on this basis.

In a paper published on EClinicalMedicine, has been assessed outcome of patients with moderate and severe COVID-19 following treatment with convalescent plasma (CP) and the association with IgG levels in transfused CP. A prospective cohort study. Primary outcome was improvement at day 14 defined as alive, not on mechanical ventilation, and moderate, mild, or recovered

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-15

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

The SARS-CoV-2 spike (S) protein variant D614G supplanted the ancestral D614 virus worldwide, reaching near fixation in a matter of months. In this paper on Cell it’s shown that D614G was more infectious than the ancestral form on human lung cells, colon cells, and on cells rendered permissive by ectopic expression of human ACE2 or

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-15

Neuroinvasion of SARS-CoV-2 in human and mouse brain

The coronavirus that causes COVID-19 can sometimes hijack brain cells, using the cells’ internal machinery to copy itself, according to a new study. The research, posted Sept. 8 to the preprint database bioRxiv, has not yet been published in a peer-reviewed journal, but it provides evidence that SARS-CoV-2 can directly infect brain cells called neurons. Although

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-15

Assessment of the immune response in kids with MIS-C, identifying candidate autoantibodies resembling antibody response to convalescent Covid.

Initially, children were thought to be spared from disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, a month into the epidemic, a novel multisystem inflammatory syndrome in children (MIS-C) emerged. In thi paper on Cell, are reported the immune profiles of nine MIS-C cases. All MIS-C patients had evidence of prior SARS-CoV-2

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-15

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

In this paper on Cell it’s shown that SARS-CoV-2 spike protein interacts with both cellular heparan sulfate and angiotensin converting enzyme 2 (ACE2) through its Receptor Binding Domain (RBD). Docking studies suggest a heparin/heparan sulfate-binding site adjacent to the ACE2 binding site. Both ACE2 and heparin can bind independently to spike protein in vitro and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-12

Racial/Ethnic Variation in Nasal Gene Expression of Transmembrane Serine Protease 2 (TMPRSS2)

In a study published in JAMA today, Mount Sinai researchers report findings that shed some light on the disproportionate impact of COVID-19 on Blacks, who have experienced rates of infection and death that are much greater, in some areas twice and three times more, than their proportion of the population. Our study suggests one factor that may

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-12

COVID-19 and the Path to Immunity

The emergence of adaptive immunity in response to the new Betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurs within the first 7 to 10 days of infection. Understanding the key features and the B-cell evolution – and T-cell-mediated adaptive immunity to SARS-CoV-2 is essential to predict the outcomes of coronavirus disease 2019 (COVID-19) and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-12

Human Mesenchymal Stromal Cells are resistant to SARS-CoV-2 Infection

Mesenchymal stem/stromal cells are not infected by SARS-CoV-2 and retain their immunomodulatory potential as published by Institute for Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service in Frankfurt am Main on Stem Cells Report. Previous studies reported safety and applicability of Mesenchymal Stem/Stromal Cells (MSC) to ameliorate pulmonary inflammation in ARDS. Thus, multiple

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-11

Rare hyperinflammatory syndrome in children with COVID-19 described

Researchers at Karolinska Institutet and Science for Life Laboratory in Sweden and Tor Vergata University of Rome in Italy have mapped the immune response in children affected by a rare but life-threatening inflammatory syndrome associated with COVID-19. The study, which is published in the scientific journal Cell, reveals that the inflammatory response differs from that

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-10

Post-COVID syndrome severely damages children’s hearts — systematic review

Multisystem inflammatory syndrome in children (MIS-C), believed to be linked to COVID-19, damages the heart to such an extent that some children will need lifelong monitoring and interventions, said the senior author of a medical literature review. Case studies also show MIS-C can strike seemingly healthy children without warning three or four weeks after asymptomatic

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-10

Obesity, diabetes and hypertension greatest risk factors for young adults with COVID-19

Young adults with underlying conditions such as morbid obesity, diabetes and hypertension are at the highest risk of being placed on a ventilator or dying from COVID-19, according to a study of 3,000 hospitalized patients aged 18 to 34. The analysis, published Wednesday in the journal JAMA Internal Medicine, focused on patients hospitalized between April and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-10

Facial Masking for Covid-19 could expose wearers to just enough of the virus that it helps trigger immunity.

SARS-CoV-2, the virus that causes COVID-19, is entirely new to infectious disease researchers and other public health scientists. To combat it, scientists have sifted through centuries of literature about how the world coped with past pandemics. A new opinion paper assesses one way in which we might be able to learn from our encounters with

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-10

Covid-19 risk tool helps guide treatment

People who are admitted to hospital with Covid-19 can be divided into four distinct groups, according to data from the world’s largest study of patients with the disease. Researchers identified the groups using clinical information and tests carried out upon arrival at hospital to predict the patients’ risk of death – ranging from low to

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-10

Convalescent plasma fails to improve outcome of COVID-19 in PLACID trial. Limits of the study.

The COVID-19 pandemic is still raging in India, with over 4.5 million cases, 75.000 deaths and more than 90,000 new cases a day. At present there are few effective therapeutic options, which means that healthcare providers are faced with ongoing challenges in managing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A new study based

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-05

Cytokine storm may not be characteristic of severe Covid-19

The strong pro-inflammatory response known as cytokine storm is said to play an important role in the pathophysiology of a severe variant of covid-19. But researchers at Radboudumc University (Matthijs Kox et al.) doubt that. In a small-scale study published in JAMA, they argue that many studies look at different cytokines and do not make a

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-05

SARS-CoV-2 ORF3b is a potent interferon antagonist and its activity is increased by a naturally occurring elongation variant

One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. In this paper it’s shown that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS-CoV ortholog. Phylogenetic analyses and functional assays reveal

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-03

SARS-CoV-2 Infection of Airway Cells and Virions production

Source: The New England Journal of Medicine In a laboratory setting, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was inoculated into human bronchial epithelial cells. This inoculation, which was performed in a biosafety level 3 facility, had a multiplicity of infection (indicating the ratio of virus particles to targeted airway cells) of 3:1. These cells

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-03

U.S. Hospitals Withstand FDA’s Directive on COVID Convalescent Plasma

Dozens of major hospitals across the U.S. are grappling with whether to ignore a federal decision allowing broader emergency use of blood plasma from recovered COVID patients to treat the disease in favor of dedicating their resources to a gold-standard clinical trial that could help settle the science for good. As many as 45 hospitals

No Comments InCovid-19

PIER MARIA FORNASARI
2020-09-02

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. Results of a WHO Meta-analysis

Treating critically ill COVID-19 patients with corticosteroid drugs reduces the risk of death by 20 percent, an analysis of seven international trials found on Wednesday, prompting the World Health Organization to update its advice on treatment. The analysis — which pooled data from separate trials of low dose hydrocortisone, dexamethasone and methylprednisolone — found that steroids improve survival

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-31

COVID-19 vaccine trials should seek worthwhile efficacy to avoid pandemic worsening

The rush to immunise populations against Covid-19 could lead to the rollout of a vaccine that is not very effective and risk worsening the pandemic, leading scientists have said. Experts, members of the WHO’s Solidarity Vaccines Trial Expert Group, which is made up of leading scientists around the world who are advising on the establishment

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-31

Patients with COVID-19 having a reduction in respiratory system compliance together with increased D-dimer concentrations have high mortality rates.

The study has been done in seven Italian Hospitals and published on The Lancet Respiratory Medicine The study confirms the role of microthrombosis in severe Covid-19, but do not explain which is the pathophysiology of the proteolytic cascades activation. For Dr. Fornasari, REGENHEALTHSOLUTIONS Director, “This study very important study shows that unhinibited proteolytic cascades activation

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-29

Children with no COVID-19 symptoms may shed virus for weeks: a new study confirms.

New research suggests that children can shed SARS-CoV-2, the virus that causes COVID-19, even if they never develop symptoms or for long after symptoms have cleared. But many questions remain about the significance of the pediatric population as vectors for this sometimes deadly disease, according to an invited commentary by Children’s National Hospital doctors that accompanies this

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-29

UK-wide study shows children with gastrointestinal symptoms should be included in COVID-19 testing

Over 1,000 children from Northern Ireland, Scotland, England and Wales, known as ‘COVID Warriors’ have had their antibodies measured in the UK-wide trial called ‘Seroprevalence of SARS-Cov-2 infection in healthy children’. The findings have been published yesterday (Friday 28 August) as a pre-print on the server medRxiv. The study is led by Queen’s University Belfast, in

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-28

Mount Sinai Team Offers Additional Data on Efficacy of Blood Anticoagulation for COVID-19 and Insight on Best Potential Regimens

Study is the basis of a new international clinical trial Early in the COVID-19 pandemic, Mount Sinai researchers were among the first to show that anticoagulation therapy was associated with improved survival among hospitalized COVID-19 patients. But many questions remained—about the size of the potential benefit, and about what dosage of this therapy might be

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-27

A study confirms: with 95% masking, 57% of Covid-19 deaths could be prevented by fall.

A new Covid-19 prediction model makes another compelling case for wearing masks and cloth face coverings. If practically everyone in America wears masks while out in public, it could prevent tens of thousands of Covid-19 infections and deaths by the fall, according to researchers at the University of Washington’s Institute for Health Metrics and Evaluation (IHME). “It is hard

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-26

To Stop COVID-19 Spread in Schools, Start with Local Data and Do the Math

Infection in General Population Mirrors Pediatric Prevalence, UCSF Study Shows Source UCSF As schools across the country continue to wrestle with configurations of online and in-classroom learning, a new study from UCSF Benioff Children’s Hospitals shows that public data and a simple equation may be all that is required to estimate the number of infected

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-25

Consistent mask- wearing could save close to 70,000 lives in the months to come in USA for NIH.

Source NIH “Masks save lives” isn’t just sound advice, it’s a scientific fact. Wearing one in public can help to slow the spread of SARS-CoV-2. Wear a mask outside home, doesn’t necessarily protect myself, but protect others. If by chance I’ve been exposed to the virus and am currently incubating it, I wouldn’t want to

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-25

Mayo Clinic Driven Expanded Access Program for Convalescent Plasma discontinues enrollment as FDA authorizes its emergency use

The Food and Drug Administration (FDA) authorized emergency use of convalescent plasma and the national Expanded Access Program (EAP) for convalescent plasma led by Mayo Clinic announced its intention to discontinue enrollment. The five-month program served 2,780 hospital and acute care facilities, with nearly 14,000 physicians enrolling 101,000 patients and reports of 71,000 infused so far. Eligible patients who

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-25

Kidney involvement by SARS-CoV-2 increases the risk of mortality and acute kidney failure.

The research presented early in the course of Corona pandemic found that Covid-19 not as initially suspected a classic viral lung disease. Rather, the whole body is affected . A team from the University Hospital Hamburg-Eppendorf (UKE) has now proven that the new coronavirus SARS-CoV-2 can also multiply in the kidneys . The novel corona virus can also multiply outside of the lungs, for example in the kidneys. Researchers at the University Medical Center

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-24

Not only antibodies: the role of B cells and T cells in mediating immunity to COVID-19

Recent reports that antibodies to SARS-CoV-2 are not maintained in the serum following recovery from the virus have caused alarm. However, the absence of specific antibodies in the serum does not necessarily mean an absence of immune memory. University of Bergen researchers have just published a paper on Nature Reviews Immunology. Immunity after infection with

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-24

FDA Covid-19 Convalescent Plasma Emergency Use Authorisation: Truth beyond Fictions

Source FDA Yesterday 08/23/2020 FDA has issued guidance to provide recommendations to health care providers and investigators on the administration and study of investigational convalescent plasma collected from individuals who have recovered from COVID-19 (COVID-19 convalescent plasma) during the public health emergency. The guidance provides recommendations on the following: pathways for use of investigational COVID-19 convalescent plasma

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-23

Risk of stroke in hospitalized SARS-CoV-2 infected patients. Results of a multinational study

There is an increased attention to stroke following SARS-CoV-2. The goal of this study was to better depict the short-term risk of stroke and its associated factors among SARS-CoV-2 hospitalized patients. This multicentre, multinational observational study includes hospitalized SARS-CoV-2 patients from North and South America (United States, Canada, and Brazil), Europe (Greece, Italy, Finland, and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-22

An uncontrolled and placebo group lacking study on 35.000 patients suggests convalescent plasma shows a 3% reduced mortality in Covid-19 patients.

Infusing hospitalized Covid-19 patients with blood plasma from people who recovered from the disease appeared to show a benefit in a nationwide study, but the study’s lack of a placebo group left several experts struggling to interpret the data. The study, which enrolled more than 35,000 patients, found that quickly administering so-called convalescent plasma had

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-21

Study analyzes how SARS-CoV-2 undermines immune defenses

A new research study used whole-genome sequencing to analyze the genetic profile of patients with the SARS-CoV-2 virus to gain more insight into how it turns the body’s own immune system against itself. The findings could help researchers develop drugs to target the virus, according to an August 3 report in Nature Medicine. Researchers focused on

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-21

Mild coronavirus infections due to SARS-CoV-2 mutation

A mutant SARS-CoV-2 variant that has appeared in East Asia appears to cause milder infections than the form without this mutation. Overall, there are initial indications that the coronavirus could weaken. As early as January and February 2020, researchers from Singapore identified a SARS-CoV-2 variant in a cluster of Covid-19 patients that had a 382 base

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-21

Triad of molecules could predict severity of COVID-19

In a new study, published in Nature Medicine, researchers at the Francis Crick Institute, King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, have found a common immune signature in the blood of patients with COVID-19, which could be used to predict how severely ill a patient will become, thereby aiding patient management. The team analysed blood samples

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-20

Effects of COVID-19 on the nervous system: a review published on Cell

Neurological complications have emerged as a significant cause of morbidity and mortality in the ongoing COVID-19 pandemic. Beside respiratory insufficiency, many hospitalized patients exhibit neurological manifestations, ranging from headache and loss of smell, to confusion and disabling strokes. COVID-19 is also anticipated to take a toll on the nervous system in the long term. In

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-20

Cytokine storm in COVID-19 patients may induce loss of transitional and follicular B cells

The release of massive amounts of proteins called cytokines can lead to some of the most severe symptoms of COVID-19. When large numbers of immune cells release cytokines, this increases inflammation and creates a feedback loop in which more immune cells are activated and this is sometimes called a cytokine storm. An August 19 study

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-17

Two existing drugs point to a potential new target against COVID-19

New lab-based studies show that two existing drugs, including one developed by a researcher at Harvard Medical School and Boston Children’s Hospital, inhibit SARS-CoV-2 — the virus that causes COVID-19 — from infecting human cells in a dish. Both drugs, vacuolin-1 and apilimod, originally developed years ago, target a large enzyme called PIKfyve kinase. Before

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-17

The six strains of SARS-CoV-2

The virus causing the COVID-19 pandemic, SARS-CoV-2, presents at least six strains. Despite its mutations, the virus shows little variability, and this is good news for the researchers working on a viable vaccine. These are the results of the most extensive study ever carried out on SARS-CoV-2 sequencing. Researchers at the University of Bologna drew

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-17

New study on JAMA Pediatrics: young kids may spread COVID-19 more efficiently than adults

A new study is challenging the idea that younger children are somehow less susceptible to SARS-CoV-2 infection. Children under the age of five have been found to carry just as much, if not more, coronavirus in their noses and throats than older kids or adults. The results, published Thursday (July 30) in JAMA Pediatrics, tested 145

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-17

What we know and don’t about Covid-19

It’s only been about seven months since the world learned a new and dangerous coronavirus was in our midst. In the time since Chinese scientists confirmed the rapidly spreading disease in Wuhan was caused by a new coronavirus and posted its genetic sequence on line, an extraordinary amount has been learned about the virus, SARS-CoV-2,

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-17

Quick and affordable saliva-based COVID-19 test developed by Yale scientists receives FDA Emergency Use Authorization

A saliva-based laboratory diagnostic test developed by researchers at the Yale School of Public Health to determine whether someone is infected with the novel coronavirus has been granted an emergency use authorization by the U.S. Food and Drug Administration (FDA). The method, called SalivaDirect, is being further validated as a test for asymptomatic individuals through

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-17

Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 following a new report by ARM

In the early days of COVID-19, the Alliance for Regenerative Medicine (ARM) was unsure how the pandemic and its accompanying economic downturn would affect the cell and gene therapy space. “It was a really specific time when the world and the markets were clearly reeling from the first appreciation for the seriousness of COVID-19,” Janet

No Comments InADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2020-08-16

Pharmacological activation of NRF2 could be a way to combat Acute respiratory distress syndrome caused by SARSCoV2.

Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine storm) and loss of T lymphocytes (lymphopenia) characterize the most aggressive presentation. A multifaceted anti-inflammatory strategy, based on pharmacological activation of nuclear factor erythroid

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-16

Important paper published on Cell by Morens and Fauci on Emerging Pandemic Diseases: How We Got To COVID-19

Infectious diseases prevalent in humans and animals are caused by pathogens that once emerged from other animal hosts. In addition to these established infections, new infectious diseases periodically emerge. In extreme cases they may cause pandemics such as COVID-19; in other cases, dead end infections or smaller epidemics result. Established diseases may also re-emerge, for

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-16

Defined the role of neutrophil extracellular traps in COVID-19 vascular occlusion. Efficacy of desamethasone, heparin and convalescent plasma.

Two papers recently published on EBioMedicine confirm that the excessive NET formation drives immunopathology in severe COVID-19 associated disseminated pulmonary intravascular coagulopathy. Coronavirus induced disease 2019 (COVID-19) can be complicated by severe organ damage leading to dysfunction of the lungs and other organs. The processes that trigger organ damage in COVID-19 are incompletely understood. Samples

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-15

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Important study on T cells in SARSCoV2 published in Cell from Marcus Buggert et al. CIM Sweden Karolinska Institute. SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. In this paper are systematically mapped the functional and phenotypic landscape of SARS-CoV-2-specific T cell responses in unexposed individuals, exposed family members,

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-05

NIH will test synthetic monoclonal antibodies and other experimental therapeutics for mild and moderate COVID-19

Initial clinical trial to determine if monoclonal antibodies can shorten severity of COVID-19 in outpatients. Source NIH A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-28

Singapore scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 & SARS patients, and in uninfected individuals

Singapore study shows that SARS-CoV-2-specific T cells are present in all recovered COVID-19 patients. These T cells were also found in all subjects who recovered from SARS 17 years ago, and in over 50% of both SARS-CoV-1 and SARS-CoV-2 uninfected individuals tested, suggesting that a level of pre-existing SARS-CoV-2 immunity is present in the general

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-25

Researchers of UT Health San Antonio found SARS-Cov-2 makes itself unrecognizable to cells

With an alarm code, we can enter a building without bells going off. It turns out that the SARS coronavirus 2 (SARS-CoV-2) has the same advantage entering cells. It possesses the code to waltz right in. On July 24 in Nature Communications, researchers at The University of Texas Health Science Center at San Antonio (UT Health

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-25

Ineffectiveness of Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy ofthese therapies is limited. A multicenter, randomized, open-label, three-group, controlled trial was conducted involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-25

Rare TLR7 Variants Implicated in COVID-19 Severity in Case Study of Affected Brothers

Rare genetic alterations in the TLR7 gene may have predisposed two sets of brothers to falling severely ill with COVID-19, a new research has found. People infected with SARS-CoV-2 exhibit a range of symptoms, and while age, sex, and comorbidities such as diabetes and obesity may predispose patients to more severe disease, there is emerging

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-23

High-dose glucocorticoids and IL-6 receptor inhibition reduce COVID-19-associated cytokine storm mortality

The Annals of the Rheumatic Diseases, the journal of the European League Against Rheumatism, EULAR, has published findings of an observational study on the treatment of patients with COVID-19-associated Cytokine storm syndrome (CSS). The study demonstrates that a treatment strategy combining intensive immunosuppression (using glucocorticoids and an IL-6 inhibitor) as well as close monitoring dramatically improves

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-22

Six symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app

An analysis of data obtained from a symptom tracker app has shown that there are six distinct “types” of covid-19, each distinguished by a cluster of symptoms. The researchers said that these types could be used to predict the need for respiratory support in severe covid-19. The study is available online as a preprint and

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-21

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

A recent article suggested the rapid decay of anti–SARS-CoV-2 IgG in early infection, but the rate was not described in detail. In this correspondence just published on The New England Journal a total of 31 of the 34 participants had two serial measurements of IgG levels and the remaining 3 participants had three serial measurements.

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-21

International Society Thrombosis and Hemostasis Experts Explain New Blood Clotting Phenomenon in Hospitalized COVID-19 Patients

As the world continues to learn more about COVID-19, emerging data reveals that hospitalized patients with COVID-19 have an increased risk for blood clots. In a new Illustrated Review published in Research and Practice in Thrombosis and Haemostasis (RPTH) , leading thrombosis experts Prof. Beverley Hunt, OBE, and Prof. Marcel Levi, explain a clotting phenomenon found in most hospitalized

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-20

Korean study shows teenagers may transmit COVID-19 as much as adults do

Since the early days of the coronavirus pandemic, scientists and health authorities have often observed that children do not appear to contract and transmit the virus to the same extent as adults. While the mechanisms behind this reduced vulnerability have remained somewhat mysterious and speculative, new evidence from South Korea shows that the age of children is also a vital factor to

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-20

Covid-19 and convalescent plasma treatment potential: the NIH position

Recommendation There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of COVID-19 convalescent plasma for the treatment of COVID-19. Rationale for Recommendation Thousands of patients in the United States have received COVID-19 convalescent plasma through clinical trials, expanded access treatment trials, and single-patient Emergency Investigational New

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-19

A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report

Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases reported, the patient continued to deteriorate even after administration of

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-19

Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study

COVID-19 is an ongoing global pandemic. Changes in haematological characteristics in patients with COVID-19 are emerging as important features of the disease. The authors aimed to explore the haematological characteristics and related risk factors in patients with COVID-19. This retrospective cohort study included patients with COVID-19 admitted to three designated sites of Wuhan Union Hospital

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-16

In severe Covid-19 deaths, autopsies point the finger at immune response

An autopsy-based study of 11 people who died from COVID-19 shows a mismatch between viral hotspots in the body and sites of inflammation and organ damage. This suggests that immune responses, rather than the virus itself, are responsible for death. The survey of 37 anatomical sites, including lungs, found that some tissues harboured the virus

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-16

Study identifies factors associated with death in critically ill COVID-19 USA patients

More than 3,5 million people in the United States have been infected with COVID-19 and more than 138,000 have died. More people have died of COVID-19 in the U.S. than in any other country, but few studies offer national data on the factors that may contribute to outcomes for critically ill patients. To address this

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-16

Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy

This study, published on JAMA, evaluates the independent risk factors associated with mortality of patients with COVID-19 requiring treatment in ICUs in the Lombardy region of Italy. This retrospective, observational cohort study includes 3988 consecutive critically ill patients with laboratory-confirmed COVID-19 referred forICU admission to the coordinating center of the COVID-19 Lombardy ICU Network from

No Comments InCovid-19

PIER MARIA FORNASARI
2020-07-15

Fragments of Life: CAR-T cells, a success in the frontier of medicine become a video game

RESTORE, a pan-European initiative that aims to accelerate the availability of Advanced Therapies for the benefit of patients and society, is working on a video game to raise awareness of the field of Advanced Therapies. One room, 60 photographs, a whole life. Ready to relive Ella’s story? Available within the next few weeks for free

No Comments InCAR-T

PIER MARIA FORNASARI
2020-07-15

Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort

Coronavirus disease 2019 (COVID-19) is associated with a high disease burden with 10% of confirmed cases progressing towards critical illness. Nevertheless, the disease course and predictors of mortality in critically ill patients are poorly understood. Following the critical developments in ICUs in regions experiencing early inception of the pandemic, the European-based, international RIsk Stratification in

No Comments InCovid-19

PIER MARIA FORNASARI
2020-06-26

Myocarditis in a 16-year-old boy positive for SARS-CoV-2

A team of University of Pavia, Italy presents on Lancet the case of 16-year-old boy admitted to emergency department, complaining of intense chest pain started 1 h earlier. The day before he had a fever of 38·3°C thatdecreased after 100 mg of nimesulide. He reported no other symptoms, no medical history, and no contact with

No Comments InCovid-19

PIER MARIA FORNASARI
2020-06-24

Covid-19:RECOVERY trial publishes preprint on dexamethasone use in ventilated patients

University of Oxford’s RECOVERY trial published its much anticipated preprint paper on the drug’s effect on Covid-19. The paper states that the drug cuts deaths in ventilated patients by one third and deaths in other admitted patients receiving oxygen by only one fifth. The headline findings of the trial were reported by the investigators on 16

No Comments InCovid-19

PIER MARIA FORNASARI
2020-06-22

Mayo Clinic finds convalescent plasma safe for diverse patients with COVID-19

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findings — from the U.S. Food and Drug Administration’s Expanded Access Program for COVID-19 — are reported in Mayo Clinic Proceedings. The safety report assessed the seven days following transfusion for hospitalized patients between April

No Comments InCovid-19

PIER MARIA FORNASARI
2020-06-18

Is severe Covid-19 risk tied to Genes and Blood Type ?

Many people who contract COVID-19 have only a mild illness, or sometimes no symptoms at all. But others develop respiratory failure that requires oxygen support or even a ventilator to help them recover [1]. It’s clear that this happens more often in men than in women, as well as in people who are older or

No Comments InCovid-19

PIER MARIA FORNASARI
2020-06-13

In JAMA Patient Page an information on Convalescent Plasma and Covid-19

Donated convalescent plasma may be beneficial to patients with severecoronavirus disease 2019 (COVID-19) to boost their ability to fight the virus. What Is Convalescent Plasma?Most people who recover from COVID-19 develop antibodies (proteins that the immune system produces in response to infection) to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). Antibodies are found in plasma,

No Comments InCovid-19

PIER MARIA FORNASARI
2020-06-10

MSC Therapy for Acute Respiratory Distress Syndrome; It’s Time to Accelerate Clinical Trials for COVID-19 Patients in Need

A new systematic review and meta-analysis of clinical studies using mesenchymal stromal cells (MSCs) led by a team at the Mayo Clinic, and including researchers from Emory, Duke, Case-Western, and the University of Miami, shows a trend toward improved outcomes and reduced mortality for patients with acute respiratory distress syndrome (ARDS)—a major complication for patients with COVID-19.

No Comments InCovid-19